A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A general term for various neoplastic diseases of the lymphoid tissue.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Mapping of the KARYOTYPE of a cell.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A notch receptor that interacts with a variety of ligands and regulates SIGNAL TRANSDUCTION PATHWAYS for multiple cellular processes. It is widely expressed during EMBRYOGENESIS and is essential for EMBRYONIC DEVELOPMENT.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The return of a sign, symptom, or disease after a remission.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.
A cell line derived from cultured tumor cells.
A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
Progenitor cells from which all blood cells derive.
Established cell cultures that have the potential to propagate indefinitely.
B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
DNA present in neoplastic tissue.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Antibodies produced by a single clone of cells.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
A transcription factor that plays a role as a key regulator of HEMATOPOIESIS. Aberrant Ikaros expression has been associated with LYMPHOBLASTIC LEUKEMIA.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Elements of limited time intervals, contributing to particular results or situations.

Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. (1/3678)

A cytogenetically cryptic (12;21) translocation is the most common molecular abnormality identified in childhood acute lymphoblastic leukemia (ALL), and it generates a chimeric TEL-AML1 protein. Fusion of the Helix-Loop-Helix (HLH) (also called the pointed) domain of TEL to AML1 has been suggested to convert AML1 from a transcriptional activator to a repressor. To define the structural features of this chimeric protein required for repression, we analysed the transcriptional activity of a series of TEL-AML1 mutants on the AML1-responsive interleukin-3 (IL-3) promoter, a potentially relevant gene target. Our results demonstrate that TEL-AML1 represses basal IL-3 promoter activity in lymphoid cells, and deletion mutant analysis identified three distinct domains of TEL-AML1 that are required for repression; the HLH (pointed) motif contained in the TEL portion of TEL-AML1, and both the runt homology domain (Rhd) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein. Although AML1B (and a shorter AML1 isoform, AML1A) have transcriptional activating activity on the IL-3 promoter, fusion of the AML1 gene to the TEL gene generates a repressor of IL-3 expression. Consistent with this activity, freshly isolated human ALL cells that contain TEL-AML1 do not express IL-3.  (+info)

Evidence of space-time clustering of childhood acute lymphoblastic leukaemia in Sweden. (2/3678)

We have examined 645 recorded cases of childhood acute lymphatic leukaemia (ALL) in Sweden during 1973-89 to identify space-time clustering by using the close-pair method of Knox. The records included date of birth and of diagnosis as well as addresses at birth and at diagnosis. There was a significant excess of case pairs close in date of birth and place of birth in the 5- to 15-year age group.  (+info)

Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study. (3/3678)

We report a population-based study of patterns of care and survival for people with acute leukaemia diagnosed at age 15-29 years during 1984-94 in regions of England and Wales covered by specialist leukaemia registries. There were 879 patients: 417 with acute lymphoblastic leukaemia (ALL) and 462 with acute myeloid leukaemia (AML). For ALL, actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Patients entered in national clinical trials and those not entered had similar survival rates. Survival rates were similar at teaching and non-teaching hospitals and at hospitals treating different numbers of study patients per year. For AML, survival rates were 42% at 5 years after diagnosis and 39% at 10 years. Survival improved significantly between 1984-88 and 1989-94. Patients entered in the Medical Research Council AML10 trial had a higher survival rate than those who were in the earlier AML9 trial. Survival did not vary with category of hospital. We conclude that survival has improved for adolescents and young adults with acute leukaemia but that there is at present no evidence that centralized treatment results in a survival benefit for patients in this age group.  (+info)

Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. (4/3678)

Although acute lymphoblastic leukemia (ALL) is the most common childhood cancer, factors governing susceptibility to this disease have not yet been identified. As such, ALL offers a useful opportunity to examine the glutathione S-transferase and cytochrome P450 genes in determining susceptibility to pediatric cancers. Both enzymes are involved in carcinogen metabolism and have been shown to influence the risk a variety of solid tumors in adults. To determine whether these genes played a similar role in childhood leukemogenesis, we compared the allele frequencies of 177 childhood ALL patients and 304 controls for the CYP1A1, CYP2D6, GSTM1, and GSTT1 genes. We chose the French population of Quebec as our study population because of its relative genetic homogeneity. The GSTM1 null and CYP1A1*2A genotypes were both found to be significant predictors of ALL risk (odds ratio [OR] = 1.8). Those possessing both genotypes were at an even greater risk of developing the disease (OR = 3.3). None of the other alleles tested for proved to be significant indicators of ALL risk. Unexpectedly, girls carrying the CYP1A1*4 were significantly underrepresented in the ALL group (OR = 0.2), suggesting that a gender-specific protective role exists for this allele. These results suggest that the risk of ALL may indeed be associated with xenobiotics-metabolism, and thus with environmental exposures. Our findings may also explain, in part, why ALL is more prevalent among males than females.  (+info)

Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. (5/3678)

The reported incidence of thromboembolism in children with acute lymphoblastic leukemia (ALL) treated with L-asparaginase, vincristine, and prednisone varies from 2.4% to 11.5%. The present study was designed to prospectively evaluate the role of the TT677 methylenetetrahydrofolate reductase (MTHFR) genotype, the prothrombin G20210A mutation, the factor V G1691A mutation, deficiencies of protein C, protein S, antithrombin, and increased lipoprotein (a) concentrations in leukemic children treated according to the ALL-Berlin-Frankfurt-Muenster (BFM) 90/95 study protocols with respect to the onset of vascular events. Three hundred and one consecutive leukemic children were enrolled in this study. Fifty-five of these 301 subjects investigated had one established single prothrombotic risk factor: 20 children showed the TT677 MTHFR genotype; 5 showed the heterozygous prothrombin G20210A variant; 11 were carriers of the factor V G1691A mutation (heterozygous, n = 10; homozygous, n = 1); 4 showed familial protein C, 4 protein S, and 2 antithrombin type I deficiency; 9 patients were suffering from familially increased lipoprotein (a) [Lp(a)] concentrations (>30 mg/dL). In addition, combined prothrombotic defects were found in a further 10 patients: the FV mutation was combined with the prothrombin G20210A variant (n = 1), increased Lp(a) (n = 3), protein C deficiency (n = 1), and homozygosity for the C677T MTHFR gene mutation (n = 1). Lp(a) was combined with protein C deficiency (n = 2) and the MTHFR TT 677 genotype (n = 2). Two hundred eighty-nine of the 301 patients were available for thrombosis-free survival analysis. In 32 (11%) of these 289 patients venous thromboembolism occurred. The overall thrombosis-free survival in patients with at least one prothrombotic defect was significantly reduced compared with patients without a prothrombotic defect within the hemostatic system (P <.0001). In addition, a clear-cut positive correlation (P <.0001) was found between thrombosis and the use of central lines. However, because the prothrombotic defects diagnosed in the total childhood population studied were all found within the prevalences reported for healthy Caucasian individuals, the interaction between prothrombotic risk factors, ALL treatment, and further environmental factors is likely to cause thrombotic manifestations.  (+info)

Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. (6/3678)

Methotrexate (MTX) is one of the most active and widely used agents for the treatment of acute lymphoblastic leukemia (ALL). To elucidate the mechanism for higher accumulation of MTX polyglutamates (MTX-PG) in hyperdiploid ALL and lower accumulation in T-lineage ALL, expression of the reduced folate carrier (RFC) was assessed by reverse transcription-polymerase chain reaction in ALL blasts isolated from newly diagnosed patients. RFC expression exhibited a 60-fold range among 29 children, with significantly higher expression in hyperdiploid B-lineage ALL (median, 11.3) compared with nonhyperdiploid ALL (median, 2.1; P <.0006), but no significant difference between nonhyperdiploid B-lineage and T-lineage ALL. Furthermore, mRNA levels of RFC (mapped by FISH to chromosome 21) were significantly related to chromosome 21 copy number (P =.0013), with the highest expression in hyperdiploid ALL blasts with 4 copies of chromosome 21. To assess the functional significance of gene copy number, MTX-PG accumulation was compared in ALL blasts isolated from 121 patients treated with either low-dose MTX (LDMTX; n = 60) or high-dose MTX (HDMTX; n = 61). After LDMTX, MTX-PG accumulation was highest in hyperdiploid B-lineage ALL with 4 copies of chromosome 21 (P =.011), but MTX-PG accumulation was not significantly related to chromosome 21 copy number after HDMTX (P =.24). These data show higher RFC expression as a mechanism for greater MTX accumulation in hyperdiploid B-lineage ALL and indicate that lineage differences in MTX-PG accumulation are not due to lower RFC expression in T-lineage ALL.  (+info)

Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. (7/3678)

Inefficient polyglutamylation is a mechanism of resistance to methotrexate (MTX) in childhood T-lineage acute lymphoblastic leukemia (T-ALL) and in acute myeloid leukemia (AML) in comparison with childhood c/preB-ALL. We analyzed the profile of MTX polyglutamylation in childhood c/preB-ALL, T-ALL, and AML (n = 45, 15, and 14, respectively), the activity of the MTX-polyglutamate synthesizing enzyme folylpolyglutamate synthetase (FPGS) (n = 39, 11, and 19, respectively) and of the MTX-polyglutamate breakdown enzyme folylpolyglutamate hydrolase (FPGH) (n = 98, 25, and 34, respectively). MTX-Glu4-6 accumulation after 24 hours exposure to 1 micromol/L [3H]-MTX in vitro was lower in T-ALL (threefold) and AML (fourfold) compared with c/preB-ALL (P +info)

A requirement for protein kinase C inhibition for calcium-triggered apoptosis in acute lymphoblastic leukemia cells. (8/3678)

We have evaluated the cytotoxicities of the combinations of calcium mobilizers and PKC inhibitors against human acute lymphoblastic leukemia (ALL) cells. Here we report that calcium mobilizers alone or PKC inhibitors alone do not induce apoptosis in human ALL cells. However, the combinations of calcium mobilizers with potent inhibitors of PKC cause significant apoptosis in ALL cells. Our results provide experimental evidence that PKC blocks Ca2+-triggered apoptosis in human ALL cells. Thus, PKC inhibitors can be used to enhance the antileukemic activity of chemical or biological agents that trigger an apoptotic calcium signal in ALL cells. The exquisite sensitivity of ALL cells to calcium-dependent apoptosis in the presence of PKC inhibitors could provide the basis for new treatment programs against ALL.  (+info)

In order to ascertain the effectiveness of nutrient rich diet and dietary counseling on the health status of pediatric acute lymphoblastic leukemia patients, this experimental study was conducted at the Institute of Radiology and Nuclear Medicine, Peshawar. A sample of 30 leukemia patients were divided into experimental and control groups based on written consents. Data regarding demographic characteristics, anthropometric measurements, and retrospective food intakes were recorded on self-constructed questionnaire. Patients in the experimental group received dietary guidelines for nutrient rich diet. Anthropometry, dietary evaluation, and blood nutrients namely serum ferritin, albumin, globulin, total protein and creatinine at 30, 60 and 90 days intervals were assessed. The data showed low height for age and low weight or height at diagnosis indicating malnourishment and wasting among all the patients. After nutritional intervention mean weights of patients in the experimental group increased ...
TY - JOUR. T1 - Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. AU - Iguchi, Akihiro. AU - Cho, Yuko. AU - Sugiyama, Minako. AU - Terashita, Yukayo. AU - Ariga, Tadashi. AU - Hosoya, Yosuke. AU - Hirabayashi, Shinsuke. AU - Manabe, Atsushi. AU - Hara, Keisuke. AU - Aiba, Tetsuya. AU - Shiokawa, Tsugumi. AU - Tada, Hiroko. AU - Sato, Norihiro. PY - 2017/4/11. Y1 - 2017/4/11. N2 - Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib ...
Relapse of childhood acute lymphoblastic leukaemia (ALL) involving the eye is a rare but challenging problem. Twenty cases occurred in patients treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia XI and ALL97 trials between 1991 and 2001, representing 2.2% of ALL relapses. Seventeen occurred as a first relapse, either in isolation or combined with relapse at another site, and three occurred as a second relapse. All patients with intraocular disease at first relapse were treated with both chemotherapy and radiotherapy, but the doses and protocols used varied. Eleven of these 17 patients are alive and in complete remission with a median follow up of 4 years 2 months from relapse. All 11 children that were treated with a full chemotherapy relapse protocol, together with local radiotherapy have survived. Patients treated with chemotherapy of shorter duration and intensity, despite radiotherapy and/or bone marrow transplantation, did poorly with only one survivor, ...
Relapse of childhood acute lymphoblastic leukaemia (ALL) involving the eye is a rare but challenging problem. Twenty cases occurred in patients treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia XI and ALL97 trials between 1991 and 2001, representing 2.2% of ALL relapses. Seventeen occurred as a first relapse, either in isolation or combined with relapse at another site, and three occurred as a second relapse. All patients with intraocular disease at first relapse were treated with both chemotherapy and radiotherapy, but the doses and protocols used varied. Eleven of these 17 patients are alive and in complete remission with a median follow up of 4 years 2 months from relapse. All 11 children that were treated with a full chemotherapy relapse protocol, together with local radiotherapy have survived. Patients treated with chemotherapy of shorter duration and intensity, despite radiotherapy and/or bone marrow transplantation, did poorly with only one survivor, currently
Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.
The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 was recently presented by a University of Pennsylvania research team at the 56th American Society of Hematology (ASH) Annual Meeting. Highlights of the new trial results include a response rate of more than 90 percent among pediatric acute lymphoblastic leukemia patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and 45 percent response rate among those with diffuse large B cell lymphoma. Dr. Carl June, the research team leader, noted, We have now treated more than 125 patients in our trials of the chimeric antigen receptor (CAR) therapy CTL019, and with each patient, we learn more and more about the potential of this therapy. The personalized cellular therapy approach begins with patients own immune cells, collected through a procedure similar to dialysis. The ...
The last few decades have turned childhood acute lymphoblastic leukaemia (ALL) from a virtually incurable disease to a disease with 80-90% survival rates. However, this has not come without a cost. Various late effects of the treatment are nowadays well acknowledged, and the survivors have increased cardiovascular (CV) morbidity and mortality. While the treatment of ALL may have direct toxic effects on various organ systems, lifestyle factors affect the CV risk of the survivors as well.. Data on CV health and fitness after treatment with common Nordic protocols since 1986 has been scarce. This thesis aimed to study CV health and fitness and the effects of a 3-month exercise intervention in 16-30-year-old long-term survivors of childhood ALL.. Fitness was poor especially in female survivors. One third reported ≤1h of moderate physical activity (PA) weekly. While the levels of other CV risk factors were similar in survivors and controls, attenuations in vascular endothelium and cardiac function ...
Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential for improving treatment strategies. Common MRD targets include immunoglobulin heavy chain or T-cell receptor gene rearrangements, recurrent cytogenetic abnormalities and mutations in important hematological genes. Whereas in the majority of adult acute lymphoblastic leukemia patients a suitable MRD target can be identified, in adult acute myeloid leukemia patients well-characterized targets are found in only half of cases. The identification of new specific molecular markers of leukemic blasts for MRD assessment, particularly in AML patients, is therefore highly desirable. Our aim was to develop a flexible strategy for mapping of cytogenetically identified unique clone-specific abnormalities down to the single nucleotide level and, based on the ...
Childhood acute lymphoblastic leukaemia (ALL) is a rare blood cancer, which affects the lymphocytic (antibody producing) white blood cells that are produced by the bone marrow.
Micromets BiTE antibody blinatumomab (MT-103) elicits a high response rate in acute lymphoblastic leukemia patients with minimal residual disease, according to the Berlin-based company. The German Multicenter Acute Lymphoblastic Leukemia Study Group (GMALL) presented phase II clinical data involving the drug at the 2009 Congress of the European Hematology Association in Berlin. 1
PRIMARY OBJECTIVES:. I. Determine the response rate of bortezomib in combination with a chemotherapy backbone of doxorubicin (doxorubicin hydrochloride), vincristine (vincristine sulfate), PEG-asparaginase (pegaspargase), and dexamethasone in patients with relapsed/refractory acute lymphoblastic leukemia.. SECONDARY OBJECTIVES:. I. Determine progression free survival. II. Estimate the rate of complete response (CR) and CR with incomplete platelet recovery (CRp) after this re-induction compared to a historical baseline.. III. Estimate failure-free survival (FFS) and survival percent at 1 year compared to a historical baseline.. IV. Assess safety and tolerability of the study drug. V. Determine whether bortezomib induces reactive oxygen species (ROS) in circulating acute lymphoblastic leukemia (ALL) blast cells.. OUTLINE:. Patients receive bortezomib subcutaneously (SC) on days 1, 4, 8, and 11; doxorubicin hydrochloride intravenously (IV) on day 1; pegaspargase IV or intramuscularly (IM) on days 5 ...
What: After reporting fourth-quarter financial results and updating investors on its clinical-drug pipeline yesterday, shares in Juno Therapeutics (NASDAQ:JUNO) were soaring 10% higher at 3:00 p.m. ET today.. So what: The clinical-stage drugmaker is knee-deep in developing next-generation cancer therapies that harness the immune system to find and destroy cancer cells.. In the fourth-quarter earnings release, management reaffirmed its goal of ushering JCAR015 for use in relapsed/refractory adult acute lymphoblastic leukemia patients to the FDA in 2017. In early-stage trials, 37 of 45 evaluable patients had a complete response to JCAR015. If Juno Therapeutics can notch similar results in its ongoing phase 2 trial, then management believes it could win accelerated FDA approval.. The company also updated investors on the progress of other drugs in its pipeline, including therapies under study for the treatment of diffuse large B-cell cancer, chronic lymphocytic leukemia, and solid organ tumor ...
Treatment for Childhood Acute Lymphoblastic Leukemia in Sewri, Mumbai. Find Doctors Near You, Book Appointment, Consult Online, View Doctor Fees, Address, Phone Numbers and Reviews. Doctors for Childhood Acute Lymphoblastic Leukemia in Sewri, Mumbai | Lybrate
Beside CRS, treatment with BABs and CAR T cells may also be compromised by CNS toxicity. These events may manifest at any time during CRS or as a singular complication [9, 10]. Therefore, staff must be made aware that an intervention with BABs or CAR T cells may potentially necessitate intubation and mechanical ventilation for airway protection, as well as antiepileptic therapy in patients with seizures [9].. A considerable proportion of patients (,50%) who received blinatumomab in a phase 2 trial for acute B-lymphoblastic leukemia experienced neurologic events such as tremor, encephalopathy, cerebellar alteration, or seizures [8]. Thirteen percent of the events were classified as severe or life-threatening. Grade ≥3 neurotoxicity was reported in 13 of 27 patients in an early clinical trial with acute lymphoblastic leukemia patients undergoing CAR T-cell therapy [11]. Recently, cases of lethal cerebral edema in those patients were observed as well [12]. The pathophysiology of these neurotoxic ...
Kite, a Gilead Company (Nasdaq: GILD), announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T (CAR T) cell therapy, which is investigational for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). With a minimum of eight weeks of follow-up, 71 percent of ALL patients (n=17/24) who received a single infusion of KTE-C19 achieved complete tumor remission (complete remission (CR) or CR with incomplete hematological recovery). The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005311/en/ ALL is an aggressive type of blood cancer which can also involve the lymph nodes, spleen, liver, central nervous system and other organs.
Kite, a Gilead Company , announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T cell therapy, which is investigational for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia .
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57 Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21 High drug attrition rates--where are we going wrong? Nat Rev Clin Oncol (2011) 5.67 Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37 The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28 Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a childrens oncology group study. J Clin Oncol (2009) 4.20 Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09 IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08 Targeting apoptosis pathways in cancer ...
TY - JOUR. T1 - Quality of life during active treatment for pediatric acute lymphoblastic leukemia. AU - Sung, Lillian. AU - Yanofsky, Rochelle. AU - Klaassen, Robert J.. AU - Dix, David. AU - Pritchard, Sheila. AU - Winick, Naomi. AU - Alexander, Sarah. AU - Klassen, Anne. PY - 2011/3/1. Y1 - 2011/3/1. N2 - The objectives of the study were to describe quality of life (QoL), identify predictors of worse QoL and examine QoL during different phases of active therapy for acute lymphoblastic leukemia (ALL). A multiinstitutional cross-sectional study was performed in children with ALL. We included children at least 2 months from diagnosis who were receiving treatment in first remission. Parents described QoL using the PedsQL 4.0 Generic Core Scales and the PedsQL 3.0 Acute Cancer Module. The 206 children on treatment for ALL had overall [median 62.5, 95% confidence interval (CI) 34.8-94.4], physical (median 62.5, 95% CI 18.8-100.0) and psychosocial (median 65.4, 95% CI 38.3-94.2) summary scores that ...
Objective: To test the hypothesis that reduced exposure to common infections in the first year of life increases the risk of developing acute lymphoblastic leukaemia. Design and setting: The United Kingdom childhood cancer study (UKCCS) is a large population based case-control study of childhood cancer across 10 regions of the UK. Participants: 6305 children (aged 2-14 years) without cancer; 3140 children with cancer (diagnosed 1991-6), of whom 1286 had acute lymphoblastic leukaemia (ALL). Main outcome measure: Day care and social activity during the first year of life were used as proxies for potential exposure to infection in infancy.. Results: Increasing levels of social activity were associated with consistent reductions in risk of ALL; a dose-response trend was seen. When children whose mothers reported no regular activity outside the family were used as the reference group, odds ratios for increasing levels of activity were 0.73 (95% confidence interval 0.62 to 0.87) for any social ...
Childhood acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many immature lymphocytes (a type of white blood cell). Childhood acute lymphoblastic leukemia (also called ALL or acute lymphocytic leukemia) is a cancer of the blood and bone marrow. This type of cancer usually gets...
Background: Obesity has been described among survivors of pediatric Acute Lymphoblastic Leukemia (ALL), especially those who have received cranial radiation. This study aims to evaluate the prevalence of overweight or obesity in pediatric ALL survivors who were not exposed to radiation, identify the time frame in which the rate of obesity rise is the greatest, and identify contributing clinical and treatment variables. Methods: In this retrospective, single institution study, the charts of 132 ALL survivors were reviewed. Odds Ratios (OR) and 95% Confidence Intervals (CI) were calculated for being overweight or obese at their 2 year follow-up for the following clinical variables: ethnicity, age at diagnosis, and weight at diagnosis. Changes in BMI percentiles between 4 different time points were assessed using t-test comparison and p values. Results: Survivors of ALL were more likely to be overweight or obese than the general population at the 2 and 5 year follow-up. White and Hispanic ethnicity and
Acute lymphoblastic leukemia is a form of leukemia or cancer of the white blood cells. Acute refers to the undifferentiated, immature state of the circulating lymphocytes (blasts) and to the rapid progression of disease, which can be fatal in weeks to months if left untreated. May be classified according to the World Health Organization (WHO). Genetic mutations involved in the pathogenesis of acute lymphoblastic leukemia are related with chromosomal translocations. Genes involved in the pathogenesis include t(9;22)(q34;q11.2) BCR-ABL1, t(v;11q23);, t(12;21)(p13;q22) TEL-AML1, t(5;14)(q31;q32)IL3-IGH and t(1;19)(q23;p13.3) TCF3-PBX1. Acute lymphoblastic leukemia must be differentiated from other diseases such as acute myelogenous leukemia, hairy cell leukemia and malignant lymphoma. In 2015 according with the National cancer institute the incidence of acute lymphocytic leukemia is 1.9 per 100,000 individuals and the case fatality rate of 2.3 per 100,000 individuals in the United States. Common ...
To date, case-control studies on the association between methylenetetrahydrofolate reductase (MTHFR) C677T and childhood acute lymphoblastic leukemia have provided either controversial or inconclusive results. To clarify the effect of MTHFR C677T on the risk of childhood acute lymphoblastic leukemia …
ASSESSMENT OF OBESITY AND HEPATIC LATE ADVERSE EFFECTS IN THE EGYPTIAN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER STUDY
ASSESSMENT OF OBESITY AND HEPATIC LATE ADVERSE EFFECTS IN THE EGYPTIAN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER STUDY
Sigma-Aldrich offers abstracts and full-text articles by [Nicholas A Vitanza, Wafik Zaky, Roy Blum, Julia A Meyer, Jinhua Wang, Teena Bhatla, Debra J Morrison, Elizabeth A Raetz, William L Carroll].
BackgroundSomatic genetic abnormalities are key initiators and drivers of disease in acute lymphoblastic leukaemia (ALL). Several chromosomal abnormalities have proven clinical utility as prognostic and predictive biomarkers at initial diagnosis. However, the role of genetic biomarkers in relapsed ALL is less well understood and has rarely been studied comprehensively within a clinical trial.AimsTo evaluate the role of genetics in predicting outcome among children with relapsed B-cell precursor ALL treated on the international trial, ALLR3.MethodsWe analysed cytogenetic, copy number alteration (CNA) and sequence mutation data at relapse in representative cohorts of patients. Patients with a very early relapse (,18 months from first diagnosis) and those patients with an isolated marrow relapse who had an early relapse (,6 months from stopping frontline therapy) were treated as clinical high risk (HR) whereas all other patients were treated as clinical standard risk (SR).ResultsClinical HR ...
Clinical trial for lymphoblastic leukemia | acute lymphocytic leukemia | Acute | Lymphoid leukemia | lymphocytic leukemia | acute lymphoblastic | childhood ALL | leukemia | acute lymphoblastic leukemia (all) | lymphatic leukaemia | acute lymphoblastic leukemia | acute lymphoid leukaemia | Lymphocytic Leukemia , An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
TY - JOUR. T1 - Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia. T2 - Implications for residual disease detection: A report from the Childrens Oncology Group. AU - Borowitz, Michael J.. AU - Pullen, D. Jeanette. AU - Winick, Naomi. AU - Martin, Paul L.. AU - Bowman, W. Paul. AU - Camitta, Bruce. PY - 2005/11. Y1 - 2005/11. N2 - Background: Flow cytometric analysis of minimal residual disease (MRD) depends on detecting phenotypically abnormal populations. However, little is known about how phenotypic shifts between diagnosis and relapse affect MRD detection in childhood acute lymphoid leukemia (ALL). Methods: We compared diagnostic and relapse bone marrow specimens in 42 children with precursor B-ALL studied with the two-tube panel CD19-APC/CD45-PerCP/CD10-PE/CD20-FITC and CD19-APC/CD45-PerCP/CD9-PE/CD34-FITC. Results: At least 29 cases bad phenotypic shifts of intensity or coefficient of variation of distribution of one or more markers. ...
Its the most common type of childhood cancer. The abnormal lymphoblasts grow quickly and replace normal cells in the bone marrow. Acute lymphoblastic leukemia (ALL) happens when the body makes too many lymphoblasts (a type of white blood cell). This article focuses on the Acute lymphoblastic leukemia (ALL) type of leukemia. Acute Lymphoblastic Leukemia. Chemotherapy is the main treatment. It usually needs to be treated as soon as possible after diagnosis. It is commonly seen in adults aged over 55-60 years. ALL is the most common type of childhood cancer, accounting for 35% of all cancers in children. Acute lymphoblastic leukaemia (ALL) is a type of blood cancer. Acute Lymphoblastic Leukemia or ALL, is a cancer that affects the bone marrow. However, the ability to dissect these evolving, heterogeneous interactions among distinct B-ALL subtypes and their varying BM niches is limited with current in vivo methods. Acute lymphocytic leukemia (ALL) is a cancer of the blood and bone marrow. This type ...
TY - JOUR. T1 - Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. AU - Gabriel, Alem. AU - Lafta, Fadhel. AU - Schwalbe, Ed. AU - Nakjang, Sirintra. AU - Cockell, Simon. AU - Iliasova, Alice. AU - Enshaei, Amir. AU - Schwab, Claire. AU - Rand, Vikki. AU - Clifford, Steven. AU - Kinsey, Sally. AU - Mitchell, Chris. AU - Vora, Ajay. AU - Harrison, Christine. AU - Moorman, Anthony. AU - Strathdee, Gordon. PY - 2015. Y1 - 2015. N2 - Although children with acute lymphoblastic leukemia (ALL) generally have a good outcome, some patients do relapse and survival following relapse is poor. Altered DNA methylation is highly prevalent in ALL and raises the possibility that DNA methylation-based biomarkers could predict patient outcome. In this study, genome-wide methylation analysis, using the Illumina Infinium HumanMethylation450 BeadChip platform, was carried out on 52 diagnostic patient samples from 4 genetic subtypes [ETV6-RUNX1, ...
TY - JOUR. T1 - Risk of adverse events in children completing treatment for acute lymphoblastic leukemia. T2 - St Jude total therapy studies VIII, IX, and X. AU - Pui, Ching Hon. AU - Dodge, Richard K.. AU - Look, A. Thomas. AU - George, Stephen L.. AU - Rivera, Gaston K.. AU - Abromowitch, Minnie. AU - Ochs, Judith. AU - Evans, William E.. AU - Crist, William M.. AU - Simone, Joseph V.. PY - 1991. Y1 - 1991. N2 - We studied the frequency, causes, and predictors of adverse events in 624 patients who had completed treatment for acute lymphoblastic leukemia (ALL) in three consecutive total therapy studies (VIII, IX, and X, 1972 to 1983). Event-free survival in study X was significantly better overall than that in studies VIII and IX (P , .0001 by the log-rank test). In study X, 75% of the patients were electively taken off therapy, compared with 54% in studies VIII and IX. However, the risks of having an adverse event during the first 5 years after completion of therapy were remarkably similar: ...
4Discussion. This study addressed the question of which are the cellular processes that sensitive leukemic cells induced to achieve tolerance to vincristine. To this end, the B-ALL cell line CCRF-SB was gradually exposed until cell proliferation was observed in the presence of 6nM vincristine, and the corresponding proteomic profile was compared to that of cells grown in the absence of the chemotherapeutic drug.. Chemoresistance may be intrinsic or acquired.18 The ability to tolerate high concentrations of chemotherapeutics of an intrinsically resistant cancer cell is not developed as a result of an exposition to the drugs; instead it is the result of genetic abnormalities the cell carries before exposition.18 By contrast, acquired chemoresistance is developed after the cancer cell is exposed to the drug and may be the result of molecular evolution of resistant clones.19 Experimental settings to study acquired chemoresistance include the comparison of matched paired samples at diagnosis and ...
Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented. Patients with a Ph chromosome, t(4;11)(q21;q23), t(8;14)(q24.1;q32), complex karyotype (5 or more chromosomal abnormalities), or low hypodiploidy/near triploidy (Ho-Tr) all had inferior rates of event-free and overall survival when compared with other patients. In contrast, patients with high hyperdiploidy or a del(9p) had a significantly improved outcome. Multivariate analysis demonstrated that the prognostic relevance of t(8;14),
Many symptoms are similar to those of more minor childhood illness. Read about the most common signs and symptoms of childhood ALL here.
Full text for this publication is not currently held within this repository. Alternative links are provided below where available. ...
TY - JOUR. T1 - Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. AU - Hosking, Fay J.. AU - Papaemmanuil, Elli. AU - Sheridan, Eammon. AU - Kinsey, Sally E.. AU - Lightfoot, Tracy. AU - Roman, Eve. AU - Irving, Julie A. E.. AU - Allan, James M.. AU - Taylor, Malcolm. AU - Tomlinson, Ian P.. AU - Greaves, Mel. AU - Houlston, Richard S.. PY - 2010/6/3. Y1 - 2010/6/3. U2 - 10.1182/blood-2009-09-244483. DO - 10.1182/blood-2009-09-244483. M3 - Article. VL - 115. SP - 4472. EP - 4477. JO - Blood. JF - Blood. SN - 0006-4971. IS - 22. ER - ...
Background: Several studies show that bone marrow (BM) microenvironment and hypoxia condition can promote the survival of leukemic cells and induce resistance to anti-leukemic drugs. However, the molecular mechanism for chemoresistance by hypoxia is not fully understood. Methods: In the present study, we investigated the effect of hypoxia on resistance to two therapies, methotrexate (MTX) and prednisolone (PRD), in two cell models for acute lymphoblastic leukemia (ALL). To look for an implication of hypoxia in chemoresistance, cell viability, total cell density and cell proliferation were analyzed. Survival and death signaling pathways were also screened by reverse phase protein array (RPPA) and western blotting experiments conducted on selected proteins to confirm the results. Results: We found that hypoxia promotes chemoresistance in both ALL cell lines. The induction of drug-resistance by hypoxia was not associated with an increase in total cell density nor an increase in cell proliferation.
Richard-Carpentier G, Kantarjian HM, Short NJ, Ravandi F, Ferrajoli A, Schroeder HM, et al. Yang J, Bhojwani D, Yang W. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. E. Jabbour has research grants with Amgen, AbbVie, Spectrum, BMS, Takeda Oncology, Pfizer, and Adaptive. Seizures 3. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pui CH, Crist WM, Look AT. PubMed Central Google Scholar. Blood. Additional tables. Neumann M, Vosberg S, Schlee C, Heesch S, Schwartz S, Gökbuget N, et al. However, a better understanding of the disease biology has generated important knowledge on the prognostic and predictive value of MRD, which has helped guide our treatment strategies, such as intensification or referral to HSCT, the use of MRD-directed novel agents or even treatment de-escalation. 2016;172(3):392-400. There ...
PRIMARY OBJECTIVES:. I. To determine the clinical activity of kinase inhibitors using pre-clinical (in-vitro) activity to select individual therapy.. SECONDARY OBJECTIVES:. I. To evaluate overall objective response rates (complete response plus partial response).. II. Determine overall survival (OS) and progression-free survival (PFS). III. Any changes in transfusion requirements.. TERTIARY OBJECTIVES:. I. Prioritize active/aberrant kinase pathways using an in vitro inhibitor screen using individual primary leukemia samples.. II. Measure on target in vivo kinase inhibition and signal transducer and activator of transcription (STAT)-5 phosphorylation and correlate with response to treatment.. III. Perform next generation sequencing (whole exome sequencing) for complete mutational analysis.. IV. Identify aberrant gene expression in primary leukemia samples from study subjects.. V. Evaluate pharmacokinetics for each individual kinase inhibitor during therapy.. OUTLINE: Patients are assigned to 1 ...
The prognosis for acute lymphoblastic leukemia (ALL) in childhood has improved considerably in the last two decades. Intensive chemotherapy soon after diagnosis has made a major contribution to this...
Lehtinen, S. S., Huuskonen, U. E., Harila-Saari, A. H., Tolonen, U., Vainionpää, L. K. and Lanning, B. M. (2002), Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia. Cancer, 94: 2466-2473. doi: 10.1002/cncr.10503 ...
BACKGROUND: The effects on long-term outcome in childhood acute lymphoblastic leukaemia (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably. With this objective the Childhood ALL Collaborative Group coordinated a worldwide overview of all randomised trials that began before 1987. METHODS: Individual patient data were sought for about 3900 children in trials of longer vs shorter maintenance (eg, 3 vs 2 years), 3700 in trials of intensive reinduction chemotherapy during maintenance, and 4400 in trials of various other questions, including 1300 in trials of pulses of vincristine and prednisone (VP) during maintenance. Analyses were of survival in first remission, overall survival, and cause-specific mortality. FINDINGS: Deaths during remission were increased by longer maintenance (2.7 percent vs 1.2 percent), VP pulses (4.0 vs 3.2 percent), and intensive reinduction (4.8 percent vs 3.3 percent), but these increases were counterbalanced by reductions in
1. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598. 2. Coustan Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696. 3. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738. 4. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782. 5. Pui CH, Relling MV, Sandlund JT, et al. Rationale and ...
The presence of TEL/AML1 fusion gene in childhood acute lymphoblastic leukaemia (ALL) defines a subgroup of patients with better than average outcome. Around 20% of the patient at point of initial ALL diagnosis are characterised by this fusion transcript from translocation t(12;21)(p12;q22). However, the prognostic significance of this aberration has recently been disputed by the Berlin-Frankfurt-Munster (BFM) study group due to its relatively high incidence found in relapsed patients (19.6% and 21.9%, in two cohorts). Here we wanted to get more data in a long term follow up retrospect investigation by analysing DNA from frozen conserved bone marrow samples of 65 children. In the study presented here only five out of 65 (7.7%) patients selected as childhood B cell precursor acute lymphoblastic leukaemia only treated according to Berlin-Frankfurt-Munster (BFM) ALL relapse trial protocols (ALL-REZ BFM 82-96) (excluding T-lineage and Philadelphia chromosome (Ph)-positive leukaemia) carry this ...
The deep remissions seen with these early study results offer promise that adults with this aggressive disease may benefit from personalized cell therapy with KTE-C19. Pending further clinical evaluation, this has the potential to be an advance for adults with no other treatment options. ZUMA-3 is an ongoing multicenter Phase 1/2 study in patients with ALL whose disease is refractory to or has relapsed following standard chemotherapy or hematopoietic stem cell transplantation. The objectives of the study are to evaluate the safety and efficacy of KTE-C19 in this patient population. At the time of data cutoff, 24 patients were evaluable for response. KTE-C19 demonstrated a 71 percent (n=17/24) rate of complete remission, with 100 percent of responders having no detectable minimal residual disease, including in those with high tumor burden and high risk genetic abnormalities. In the safety analysis of 29 patients, adverse events were consistent with the known toxicities of CD19 CAR T treatment, ...
The deep remissions seen with these early study results offer promise that adults with this aggressive disease may benefit from personalized cell therapy with KTE-C19. Pending further clinical evaluation, this has the potential to be an advance for adults with no other treatment options. ZUMA-3 is an ongoing multicenter Phase 1/2 study in patients with ALL whose disease is refractory to or has relapsed following standard chemotherapy or hematopoietic stem cell transplantation. The objectives of the study are to evaluate the safety and efficacy of KTE-C19 in this patient population. At the time of data cutoff, 24 patients were evaluable for response. KTE-C19 demonstrated a 71 percent (n=17/24) rate of complete remission, with 100 percent of responders having no detectable minimal residual disease, including in those with high tumor burden and high risk genetic abnormalities. In the safety analysis of 29 patients, adverse events were consistent with the known toxicities of CD19 CAR T treatment, ...
TY - JOUR. T1 - Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. AU - Sherborne, Amy L.. AU - Hemminki, Kari. AU - Kumar, Rajiv. AU - Bartram, Claus R.. AU - Stanulla, Martin. AU - Schrappe, Martin. AU - Petridou, Eleni. AU - Semsei, Ágnes F.. AU - Szalai, Csaba. AU - Sinnett, Daniel. AU - Krajinovic, Maja. AU - Healy, Jasmine. AU - Lanciotti, Marina. AU - Dufour, Carlo. AU - Indaco, Stefania. AU - El-Ghouroury, Eman A.. AU - Sawangpanich, Ruchchadol. AU - Hongeng, Suradej. AU - Pakakasama, Samart. AU - Gonzalez-Neira, Anna. AU - Ugarte, Evelia L.. AU - Leal, Valeria P.. AU - Espinoza, Juan P M. AU - Kamel, Azza M.. AU - Ebid, Gamal T A. AU - Radwan, Eman R.. AU - Yalin, Serap. AU - Yalin, Erdinc. AU - Berkoz, Mehmet. AU - Simpson, Jill. AU - Roman, Eve. AU - Lightfoot, Tracy. AU - Hosking, Fay J.. AU - Vijayakrishnan, Jayaram. AU - Greaves, Mel. AU - Houlston, Richard S.. PY - 2011/7. Y1 - 2011/7. N2 - Acute ...
Clinicians who perform radiation therapy (RT) are exposed to radiation, which may negatively affect their health. The present study reports a case of acute lymphoblastic leukemia in a healthcare provider who was exposed to radiation at work; we also present a literature review of this topic. A 45-year-old patient, who had been a radiation oncologist and had been exposed to radiation while performing brachytherapy 10 years ago, complained of chest pain and was suspected of having leukemia based on the results of a blood test in an outpatient clinic. He was diagnosed with acute lymphoblastic leukemia, and subsequently underwent chemotherapy. However, the case died during treatment. Through epidemiological investigation, it was found that the cases cumulative exposure dose based on personal exposure and spatial dose measured during the work period was in the range of 6.08-12.15 mSv. Based on the following considerations, acute lymphoblastic leukemia was highly correlated with the level of radiation to
TY - JOUR. T1 - Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. T2 - Childrens oncology group study AALL0031. AU - Schultz, K. R.. AU - Carroll, A.. AU - Heerema, N. A.. AU - Bowman, W. P.. AU - Aledo, A.. AU - Slayton, W. B.. AU - Sather, H.. AU - Devidas, M.. AU - Zheng, H. W.. AU - Davies, S. M.. AU - Gaynon, P. S.. AU - Trigg, M.. AU - Rutledge, R.. AU - Jorstad, D.. AU - Winick, N.. AU - Borowitz, M. J.. AU - Hunger, S. P.. AU - Carroll, W. L.. AU - Camitta, B.. N1 - Funding Information: We sincerely thank Laura Francisco for invaluable data management support, Tammie Eslinger, CCRP, for outstanding protocol development and performance support and Bernice Pasut, RN, for diligent and thorough protocol development support. SPH is the Ergen Family Chair in Pediatric Cancer. This work was supported by grants CA98543 and CA29139.. PY - 2014/7. Y1 - 2014/7. N2 - We previously reported preliminary findings that post induction imatinib ...
Improved early event-free survival with imatinib in Philadelphia chromosome - Positive acute lymphoblastic leukemia: A Childrens Oncology Group Study Academic Article ...
The aim of this study is to evaluate the long term survival outcomes in patients with Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
TY - JOUR. T1 - Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia. T2 - A review. AU - Bachanova, V.. AU - Weisdorf, D.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2008/3. Y1 - 2008/3. N2 - Acute lymphoblastic leukemia is highly sensitive to induction chemotherapy; however, long-term survival in adults has been less than 35%, primarily as a result of high relapse rate. Treatment for relapsed disease is even less successful. The optimal post-remission therapy in the first complete remission offers the best opportunity for leukemia-free survival. Allogeneic donor stem cell transplantation can offer a unique anti-leukemia effect and a potential for extended survival. We will discuss advances in unrelated donor (URD) stem cells transplantation, improvements in transplantation process and supportive care along with growing experience with umbilical cord blood (UCB) allografts.. AB - Acute lymphoblastic leukemia is highly sensitive to ...
Similar to most cancers, genome-wide DNA methylation profiles are commonly altered in pediatric acute lymphoblastic leukemia (ALL); however, recent observations highlight that a large portion of malignancy-associated DNA methylation alterations are not accompanied by related gene expression changes. By analyzing and integrating the methylome and transcriptome profiles of pediatric B-cell ALL cases and primary tissue controls, we report 325 genes hypermethylated and downregulated and 45 genes hypomethylated and upregulated in pediatric B-cell ALL, irrespective of subtype. Repressed cation channel subunits and cAMP signaling activators and transducers are overrepresented, potentially indicating a reduced cellular potential to receive and propagate apoptotic signals. Furthermore, we report specific DNA methylation alterations with concurrent gene expression changes within individual ALL subtypes. The ETV6-RUNX1 translocation was associated with downregulation of ASNS and upregulation of the ...
When you donate blood or platelets at the Kraft Family Blood Donor Center at Dana-Farber Cancer Institute and Brigham and Women's Hospital, or give blood on board the Dana-Farber Cancer Institute/Brigham and Women's Hospital Blood Mobile, you are making a life-saving difference for patients in need - right here in our community.
TY - JOUR. T1 - Six candidate miRNAs associated with early relapse in pediatric b-cell acute lymphoblastic leukemia. AU - Amankwah, Ernest K.. AU - Devidas, Meenakshi. AU - Teachey, David T.. AU - Rabin, Karen R.. AU - Brown, Patrick A.. PY - 2020/6. Y1 - 2020/6. N2 - Background/Aim: Few studies have evaluated the role of miRNAs in pediatric acute lymphoblastic leukemia (ALL) relapse and a consensus of a clinically significant miRNA signature is yet to be identified. In this study, we evaluated miRNAs associated with pediatric B-ALL early relapse in two independent sample sets. Materials and Methods: We performed global miRNA profiling on diagnostic bone marrow specimens from six early relapse (?3 years after diagnosis) and six age- and cytogenetics-matched prolonged remission (?4 years) patients (first set) and an independent set of 14 early relapse and 14 matched prolonged remission specimens (second set). Results: Twelve and 39 top differentially expressed miRNAs were observed in the first ...
Even in the tyrosine kinase inhibitor era, allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as standard care for adult Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL). In this retrospective national study, we have reviewed the outcome after HSCT in Sweden for adult Ph-positive ALL between 2000 and 2009. In total, 51 patients with median age 42 (range 20-66) years underwent HSCT. Mainly allogeneic HSCT was performed (24 related donor, 24 unrelated donor and one cord blood), and only two patients were treated with an autologous HSCT. The 5-year OS was 51 (37-64) %. The probabilities of morphological relapse and non-relapse mortality (NRM) at 5 years were 36 (23-49) and 18 (9-29) %, respectively. For the allogeneic transplanted, the 5-year OS was for patients ,40 years 70 (50-90) % and for patients ,= 40 years 34 (16-52) %, p = 0.002. The 5-year probability of NRM was for patients ,40 years 10 (2-28) % compared to 25 (11-42) % for patients ,= 40 years (p = 0.04). ...
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low, said Richard Pazdur, M.D., director of the FDAs Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDAs Center for Drug Evaluation and Research. These patients have few treatments available and todays approval provides a new, targeted treatment option.. B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. The National Cancer Institute estimates that approximately 5,970 people in the United States will be diagnosed with ALL this year and approximately 1,440 will die from the ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
At the 59th American Society of Hematology (ASH) Annual Meeting & Exposition, Hunger et al presented data from the phase II CA180-372 study in pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) treated with dasatinib (Sprycel) added to a chemotherapy regimen modeled on a Berlin-Frankfurt-Munster high-risk backbone (Abstract 98). The combination demonstrated an event-free survival rate (the studys primary endpoint) of 65.5% (95% confidence interval [CI] = 57.7-73.7) and an overall survival rate of 91.5% (95% CI = 84.2-95.5) at 3 years. Dasatinib and chemotherapy were generally well tolerated in pediatric Philadelphia chromosome-positive ALL patients.. Philadelphia chromosome-positive acute lymphoblastic leukemia remains a high-risk leukemia type, said lead study author Stephen Hunger, MD, Chief of the Division of Oncology and Director of the Center for Childhood Cancer Research at Childrens Hospital of Philadelphia. In this study, the ...
Dana-Farber employs more than 4,274 full-time and part-time people, 467 faculty, and has annual gross revenues of about $1,086,638,000.[1] There are more than 299,202 adult and pediatric patient visits a year, and it is involved in more than 700 clinical trials. It is internationally known for its research and clinical excellence. Expertscape ranks its programs in aplastic anemia[2] and multiple myeloma[3] as best in the world. It has been also ranked the fourth best cancer hospital in the United States by U.S. News & World Report.[4] Dana-Farber is a member of the Multiple Myeloma Research Consortium. In addition to being a principal teaching affiliate of Harvard Medical School, Dana-Farber is also a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC),[5] a federally designated Comprehensive Cancer Center. Providing advanced training in cancer treatment and research for an international faculty, Dana-Farber conducts ...
TY - JOUR. T1 - Clinical Utility of Initial Terminal Deoxynucleotidyl Transferase Determinations in Childhood Acute Leukemias. AU - Kalwinsky, David K.. AU - Weatherred, William H.. AU - Dahl, Gary V.. AU - Bowman, W. Paul. AU - Melvin, Susan L.. AU - Coleman, Mary Sue. AU - Bollum, F. J.. PY - 1981/7/1. Y1 - 1981/7/1. N2 - Terminal deoxynucleotidyl transferase (TDT) activity was measured in bone marrow lymphoblasts obtained at diagnosis from 168 consecutive patients with childhood acute leukemia. Absolute concentrations of TDT were increased (,20 units/108 blasts) in samples from 98 of 112 assessable patients with acute lymphocytic leukemia (ALL). The values ranged from ,1 to 1502 units/108 blasts with a median of 90 units contrasted with ,1 to 219 units (median, 2.6 units) in studies of children without leukemia. Results of an immunofluorescence assay were in good agreement with enzymatic detection of the polymerase. Among 115 patients with adequate marrow smears, 105 had TDT-positive blasts. ...
In vitro and in vivo resistance to prednisolone are predictive for an adverse prognosis in pediatric precursor-B acute lymphoblastic leukemia. Causes of resistance are still poorly understood. In this study, we observed that prednisolone exposure of prednisolone-sensitive patients leukemic cells decreased anti-apoptotic MCL1 protein levels by 2.9-fold, while MCL1 protein expression in prednisolone-resistant leukemic patients cells was unaffected (p,0.01). Locked nucleic acid oligonucleotides directed against MCL1 (MCL1 LNA) reduced MCL1 protein levels by 82 +/- 16% (p,0.05) in leukemic cells, decreased proliferation by 9-fold and sensitized to prednisolone up to 80.8-fold, compared to a non-silencing-control LNA (p,0.05). Remarkably, we discovered that MCL1-silencing upregulated the glucose consumption of leukemic cells by 2.5-fold (p,0.05), suggesting a potential rescue mechanism mediated by glycolysis. Targeting glycolysis by 2-deoxyglucose (2-DG) synergistically inhibited leukemic survival ...
BOSTONThe Dana-Farber Cancer Institute and the National Foundation for...With eight other NFCR research centers at universities and research ho...How the Center Works...Traditionally monoclonal antibodies have been derived from mouse mode...,Dana-Farber,launches,NFCR,Center,for,Therapeutic,Antibody,Research,and,Engineering,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens. METHODS: This open-label randomised trial was undertaken in 22 centres in the UK and Ireland and nine in Australia and New Zealand. Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype. All patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation. Neither patients nor those giving interventions were masked. After three blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal residual disease (≥10(-4)
BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens. METHODS: This open-label randomised trial was undertaken in 22 centres in the UK and Ireland and nine in Australia and New Zealand. Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype. All patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation. Neither patients nor those giving interventions were masked. After three blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal residual disease (≥10(-4)
2017 PCF Challenge Award ($1 Million) Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, PhD (Memorial Sloan Kettering Cancer Center), Maika Mitchell, PhD (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, PhD (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, PhD (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, PhD (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Womens Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, PhD (Memorial Sloan Kettering Cancer Center), Michaela Bowden, PhD (Harvard: Dana-Farber Cancer ...
Karyotype analysis of acute lymphoblastic leukemia (ALL) at diagnosis has provided valuable prognostic markers for treatment stratification. However, reports of cytogenetic studies of relapsed ALL samples are limited. We compared the karyotypes from 436 nonselected B-cell precursor ALL patients at initial diagnosis and of 76 patients at first relapse. We noticed a relative increase of karyotypes that did not fall into the classic ALL cytogenetic subgroups (high hyperdiploidy, t(12;21), t(9;22), 11q23, t(1;19), ,45 chromosomes) in a group of 29 patients at relapse (38%) compared to 130 patients at presentation (30%). Non-classical cytogenetic aberrations in these 29 patients were mostly found on chromosomes 1, 2, 7, 9, 13, 14, and 17. We also describe six rare reciprocal translocations, three of which involved 14q32. The most frequent abnormalities were found in 9p (12/29 cases) and were associated with a marked decrease in the duration of the second remission, but not of the probability of ...
TY - JOUR. T1 - Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome. AU - Goto, Hiroaki. AU - Kaneko, Takashi. AU - Shioda, Yoko. AU - Kajiwara, Michiko. AU - Sakashita, Kazuo. AU - Kitoh, Toshiyuki. AU - Hayakawa, Akira. AU - Miki, Mizuka. AU - Kato, Keisuke. AU - Ogawa, Atsushi. AU - Hashii, Yoshiko. AU - Inukai, Takeshi. AU - Kato, Chiaki. AU - Sakamaki, Hisashi. AU - Yabe, Hiromasa. AU - Suzuki, Ritsuro. AU - Kato, Koji. PY - 2015/1/1. Y1 - 2015/1/1. N2 - Background: Hematopoietic stem cell transplantation (HSCT) is one curable option for high-risk acute lymphoblastic leukemia (ALL); however, transplant-related toxicities might be severe in patients with Down syndrome and ALL (DS-ALL). Procedure: HSCTs performed in patients with DS-ALL were identified in the Japan Society for Hematopoietic Cell Transplantation registry. Results: In the registry data, 11 patients with DS-ALL were identified. The median age at HSCT was 9 years (range: 6-22 ...
Method A population-based case-control study of childhood ALL was conducted in Australia. Information about the occupational pesticide exposure of mothers and fathers was collected using job-specific modules. Information on the types and extent of pesticide exposure was collected for mothers and fathers before and around the time of conception, and also for mothers during pregnancy for the index case or control and for 1 year after birth.. ...
Järviaho T, Bang B, Zachariadis V, Taylan F, Moilanen J, Möttönen M, Smith CIE, Harila-Saari A, Niinimäki R, Nordgren A Blood Adv 3 (18) 2722-2731 [2019-09-24; online 2019-09-15] Pathogenic germline variants in ETV6 have been associated with familial predisposition to thrombocytopenia and hematological malignancies, predominantly childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In addition, overrepresentation of a high hyperdiploid subtype and older age at diagnosis have been reported among sporadic BCP-ALL cases with germline variants in ETV6 We studied a family with 2 second-degree relatives who developed childhood high hyperdiploid BCP-ALL at ages 8 and 12 years, respectively. A constitutional balanced reciprocal translocation t(12;14)(p13.2;q23.1) was discovered in both patients by routine karyotyping at diagnosis and, subsequently, in 7 healthy family members who had not experienced hematological malignancies. No carriers had thrombocytopenia. Whole-genome sequencing ...
A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Childhood acute lymphoblastic leukemia
Kimmie Ng, MD, MPH Find a cancer doctor with Dana Farbers physician directory. Read how to search for a cancer doctor by name for breast cancer, cervical cancer, ovarian cancer, lung cancer, stomach cancer, testicular cancer, prostate cancer, sarcoma, lymphoma, leukemia, brain tumor, melanoma, bladder cancer, blood disorders, skin cancer, colon cancer, and more at Dana-Farber Cancer Institute.
A variety of efforts are underway to apply gene therapy to cancer treatment. Most are in early, exploratory stages, where theyre being studied in the laboratory or in clinical research trials. One approach, however, known as CAR T-cell therapy, has received approval from the U.S. Food and Drug Administration for use as a therapy in certain groups of patients and is expected to receive additional approvals in the near future.. Research in gene therapy for cancer is currently focused in multiple areas, including genetically engineered viruses that directly kill cancer cells, gene transfer to alter the abnormal functioning of cancer cells, and immunotherapy (which includes CAR T-cell therapy), which helps the immune system better find and kill tumor cells.. Learn more about immunotherapy from the Center for Immuno-Oncology at Dana-Farber Cancer Institute.. Genetically Engineered Viruses. This approach uses specially modified viruses (called oncolytic viruses) that target and destroy cancer cells ...
2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, PhD (Memorial Sloan Kettering Cancer Center), Maika Mitchell, PhD (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, PhD (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, PhD (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, PhD (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Womens Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, PhD (Memorial Sloan Kettering Cancer Center), Michaela Bowden, ...
Results: A positive correlation was demonstrated between cfDNA and age (p=0.018; r=0.177). Pre-transplant cfDNA levels were found to be lower in bcr-abl (+) patients (p=0.001), whilst an adverse correlation was indicated between cfDNA and bcr-abl levels (p=0.001; r=-0.531). Akut lymphoblastic leukemia patients with bcr-abl positivity (p=0.001) or abnormal cytogenetics (p=0.038) represented signficantly lower pre-transplant cfDNA levels. Cell free DNA levels were lower in patients who developed sinusoidal obstruction syndrome (p=0.035). In terms of long term complications, acute myeloid leukemia patients who experienced post-transplant relapse had significantly lower pre-transplant cfDNA levels (p=0.024). Overall survival was not statistically different between high- and low-cfDNA groups (45.2% vs 22.5; p=0.821 ...
Results: A positive correlation was demonstrated between cfDNA and age (p=0.018; r=0.177). Pre-transplant cfDNA levels were found to be lower in bcr-abl (+) patients (p=0.001), whilst an adverse correlation was indicated between cfDNA and bcr-abl levels (p=0.001; r=-0.531). Akut lymphoblastic leukemia patients with bcr-abl positivity (p=0.001) or abnormal cytogenetics (p=0.038) represented signficantly lower pre-transplant cfDNA levels. Cell free DNA levels were lower in patients who developed sinusoidal obstruction syndrome (p=0.035). In terms of long term complications, acute myeloid leukemia patients who experienced post-transplant relapse had significantly lower pre-transplant cfDNA levels (p=0.024). Overall survival was not statistically different between high- and low-cfDNA groups (45.2% vs 22.5; p=0.821 ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... The most common T-cell leukemia is precursor T-cell lymphoblastic leukemia.[1] It causes 15% of acute leukemias in childhood, ... 9940/3 - Hairy cell leukemia. T-cell leukemias[edit]. T-cell leukemia describes several different types of lymphoid leukemias ... T-cell prolymphocytic leukemia. In practice, it can be hard to distinguish T-cell leukemia from T-cell lymphoma, and they are ...
"Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias". Am. J. Clin. Pathol. ... "Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias". Am. J. Clin. Pathol. ... the acute leukemia could be acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). According to the original EGIL ... Persistent fever, infection prolonged healing: Most of the white blood cells are leukemia cells, no normal function, leading to ...
"Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma. ". Chin J Cancer. 2010. PMID 20193116. ... "Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the ... "Identification of MNDA as a new marker for nodal marginal zone lymphoma.". Leukemia. 2009. PMID 19474799. ... cnewyllyn cell. • extracellular region. • nucleoplasm. • nucleolus. • azurophil granule lumen. • ficolin-1-rich granule lumen. ...
... precursor t-cell acute lymphoblastic leukemia, beichiogrwydd ectopig, polymyositis, diffuse large b-cell lymphoma, t-cell ... central nervous system lymphoma, precursor b-cell acute lymphoblastic leukemia, pemffigaidd pothellog ... precursor t-lymphoblastic lymphoma/leukemia, granulomatosis wegener, liwcemia myeloid aciwt, ... b-cell lymphoma, osteoarthritis susceptibility 1, gwynegon, temporal arteritis, systemic-onset juvenile idiopathic arthritis, ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Anaplastic large-cell lymphoma is an example of a large-cell lymphoma that involves T cells. Of the large-cell T-cell lymphomas ... B cell[edit]. Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase " ... which are often diffuse large-B-cell lymphomas. Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Anaplastic large-cell lymphoma (ALCL) is a form of cancer. It is a type of non-Hodgkin lymphoma involving aberrant T cells or ... The cells are also typically positive for a subset of markers of T-cell lineage. However, as with other T-cell lymphomas, they ... It has been suggested that ALK-negative anaplastic large-cell lymphomas derive from other T-cell lymphomas that are morphologic ...
... a wide range of acquired mutations in hematological precursor cells that lead to various types of leukemia and/or lymphoma. It ... chronic myelomonocytic leukemia, acute myelocytic leukemia, B cell acute lymphoblastic leukemia, mixed phenotype acute leukemia ... Sanchez-Martin M, Ferrando A (March 2017). "The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia". Blood. 129 (9 ... of adult T cell Acute lymphoblastic leukemia cases. These mutations involve insertions or deletions in the gene that lead to ...
... is used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is administered ... In May 2013, a phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not ... is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia ( ... and the FDA for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia ...
Lymphomas or leukemias of thymocyte origin are classified as Precursor T acute lymphoblastic leukemia/lymphoma (T-ALL). People ... These syndromes are caused by defective hematopoietic progenitor cells which are the precursors of both B- and T cells. This ... Cells in the thymus can be divided into thymic stromal cells and cells of hematopoietic origin (derived from bone marrow ... Stromal cells include epithelial cells of the thymic cortex and medulla, and dendritic cells. The thymus provides an inductive ...
"BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia". "U. ... "FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma". FDA. ... S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R B-cell precursor Acute Lymphoblastic Leukemia". ADC ... monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia ...
... the lymphoproliferative disorders acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma.[ ... Chronic eosinophilic leukemia (not otherwise specified) MPN, unclassifiable (MPN-U) MPNs arise when precursor cells (blast ... Chronic neutrophilic leukemia Chronic neutrophilic leukemia (CNL) is characterized by a mutation in the CSF3R gene and an ... Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or ...
... acute lymphoblastic leukemia (ALL), hairy cell leukemia, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, and ... Malignant transformation of B cells and their precursors can cause a host of cancers, including chronic lymphocytic leukemia ( ... B-2 cell - FO B cells and MZ B cells. Follicular (FO) B Cell (also known as a B-2 cell) - Most common type of B cell and, when ... T cells and natural killer cells, express B cell receptors (BCRs) on their cell membrane. BCRs allow the B cell to bind to a ...
Acute erythroid leukemia Acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia Adult T-cell leukemia/lymphoma ( ... Precursor) T-lymphoblastic leukemia/lymphoma Blast crisis of chronic myelogenous leukemia Wolach, O; Stone, R. M. (2015). "How ... Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original diagnosis of leukemia. In ... Forms of acute leukemia include: Acute myeloid leukemia ... of the malignant cells that grow uncontrolled, but some are ...
Precursor B lymphoblastic leukemia 9940/3 - Hairy cell leukemia T-cell leukemia B-cell lymphoma. ... B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 9826/3 - Acute lymphoblastic leukemia, mature B-cell type 9833/3 ... A B-cell leukemia is any of several types of lymphoid leukemia which affect B cells. Types include (with ICD-O code): 9823/3 - ...
However, tumor cells in some cases of T-lymphoblastic leukemia/lymphoma and AML has shown to potentially react positively with ... expressed by B-cell and plasma cell precursors is a candidate that induces apoptosis as well as inhibition of B-cell receptor ( ... "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma". Nature. 463 (7277): 88-92. Bibcode:2010Natur.463 ... CD79 serves to be a pan-B cell marker for the detection of B-cell neoplasms. ...
... of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia ... DNA sequencing of miR-17-92 cluster at chromosome 13q31-q32 in mantel cell lymphoma cell lines]". Zhongguo Shi Yan Xue Ye Xue ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ...
T-cell acute lymphoblastic leukemia * B-cell lymphomas * Cell lines * Cerebellum * Purkinje cells * HeLa cells Finally they ... MiR-19 is sufficient to induce T-cell lymphoblastic leukemia activating Notch1 and accelerate the disease. Its targets are: * ... which provides new clues for sustained activation of NF-kB in T-cell acute lymphoblastic leukemia. ... demonstrated that the expression of endogenous miR-17-92 is required to suppress apoptosis in Myc-driven B-cell lymphomas. More ...
It is the most common type of acute lymphoblastic leukemia (ALL). It is sometimes additionally classified as a lymphoma, as ... Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white ... Precursor B-lymphoblastic leukemia entry in the public domain NCI Dictionary of Cancer Terms v t e v t e. ... as capable to change phenotype of B cells toward precursor cells. {{,t(12;21)-ETV/ CBFα has a better prognosis as compared to ...
Hepatocellular carcinoma Chronic lymphocytic leukemia Acute lymphoblastic leukemia Acute myeloid leukemia gastric MALT lymphoma ... "Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and ... More specifically, miR-223 expression suppresses the differentiation of osteoclast precursors into osteoclast thus making it a ... acute lymphoblastic leukemia, acute myeloid leukemia, gastric MALT lymphoma, and recurrent ovarian cancer. Integrative analysis ...
... precursor B-cell lymphoblastic leukemia, plasmablastic lymphoma, the high grade subtype of B-cell lymphoma, Hodgkin lymphoma of ... the high grade subtype of B-cell lymphoma, Hodgkin lymphoma of the B-cell type, chronic lymphocytic leukemia/small cell ... or in rare cases exhibit the histology resembling precursor B-cell lymphoblastic leukemia, plasmablastic lymphoma, ... FL may be confused with marginal zone B-cell lymphoma, mantle cell lymphoma, and the small lymphocytic lymphoma variant of ...
B-cell lymphoma, T-cell lymphomas, T cell leukemias, and Langerhans cell histiocytosis. Other hematological diseases are ... Hematopoietic stem cells give rise to: 1) myeloid precursor cells that differentiate into red blood cells, mast cells, blood ... acute myelogenous leukemia, acute lymphoblastic leukemia, or T lymphoblastic lymphoma. These patients usually respond well to ... Such mutations occur in hematological stem cells and/or their daughter myeloid precursor and lymphoid precursor cells; commonly ...
... is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is ... large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise ... is a medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight ... The T cells are engineered to target a protein called CD19 that is common on B cells. A chimeric T cell receptor ("CAR-T") is ...
... large-cell lymphomas, chronic lymphocytic leukemia and acute lymphoblastic leukemia. Toxicity against CD19 results in B cell ... though the expression of these molecules on normal precursors can lead to prolonged myeloablation. BCMA is a tumor necrosis ... Antigen CD19 appears only on B cells, which go awry in lymphoma and leukemia. Loss of B cells can be countered with ... CD4+ T cells can also promote tumor rejection. CD4+ T cells enhance CD8+ T cell function and can directly destroy tumor cells. ...
... malignancy Acute lymphoblastic leukemia Chronic myelogenous leukemia Eosinophilic leukemia Clonal eosinophilia Hodgkin lymphoma ... Maintenance of these levels results from a balance between production of eosinophils by bone marrow eosinophil precursor cells ... In primary cutaneous T cell lymphoma, blood and dermal eosinophilia are often seen. Lymphoma cells have also been shown to ... chronic myelomonocytic leukemia, and certain cases of T-lymphoblastic leukemia/lymphoma-associated or myelodysplastic- ...
... cell linages present with signs and symptoms respectively of acute myeloid leukemia or lymphoma T-lymphoblastic leukemia/ ... occurs in lymphoid precursor cells to promote the proliferation and differentiation of precursor cells along the lymphoid ... while occurring in myeloid precursor cells, promotes proliferation and differentiation of precursor cells along the neutrophil ... the success of Gleevec in treating the myeloproliferative neoplasm/myeloblastic leukemia or T-lymphoblastic leukemia/lymphoma ...
"Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells". ... "Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active ... positive childhood T-cell acute lymphoblastic leukemia". European Journal of Haematology. 77 (1): 27-34. doi:10.1111/j.0902- ... "Entrez Gene: [email protected] T cell receptor delta locus". Chien YH, Iwashima M, Kaplan KB, Elliott JF, Davis MM (1987). "A new T-cell ...
Because precursor B cell and precursor T cells look the same, immunophenotyping can help differentiate the subtype of ALL and ... DeAngelo DJ, Pui C. Acute lymphoblastic leukemia and lymphoblastic lymphoma. Chapter 19 of American Society of Hematology Self- ... T cell or pre-B cell Large and heterogeneous (varied) cells ALL - L3 B cell Large and varied cells with vacuoles Mature B-cell ... a b c Acute Lymphoblastic Leukemia at eMedicine *^ Bleyer WA (August 1988). "Central nervous system leukemia". Pediatric ...
... which is approved by the US FDA for treatment of relapsed/refractory acute lymphoblastic leukemia. He has invented various ... "Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor". Cell. 53 (2): 211 ... Perkel, Jeffrey (2008-08-14). "New Lymphoma Drug Shows Promise". ISSN 0190-8286. Retrieved 2017-10-04. "TCR2 Therapeutics ... University of Konstanz Max-Planck Institute of Molecular Cell Biology and Genetics Max-Planck Institute for Neurobiology EMBL ...
Downregulation of miR16 (as well as miR15) was observed in diffuse large B-cell lymphoma. miR16 has been shown to bind to a ... "Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant ... Caligaris-Cappio F, Hamblin TJ (1999). "B-cell chronic lymphocytic leukemia: a bird of a different feather". J Clin Oncol. 17 ( ... "Accumulation of miR-155 and BIC RNA in human B-cell lymphoma". Proc Natl Acad Sci U S A. 102 (10): 3627-3632. doi:10.1073/pnas. ...
... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... The Lymphomas (PDF). The Leukemia & Lymphoma Society: 2. May 2006 [2008-04-07]. (原始内容 (PDF)存档于2008-07-06).. 已忽略未知参数. ,url- ... Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells. The Journal of Biological Chemistry ... T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer ...
... acute lymphoblastic leukemia, Cri-du-chat, Velocardiofacial syndrome, and Down syndrome. FISH on sperm cells is indicated for ... such as translocations and inversions which are hallmark aberrations seen in many types of leukemia and lymphoma. ... "Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity". RNA. 17 (6): ... A metaphase cell positive for the bcr/abl rearrangement (associated with chronic myelogenous leukemia) using FISH. The ...
... for B-cell acute lymphoblastic leukemia [109] Proteasome inhibitors can kill some types of cultured leukemia cells that are ... "Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in ... Schenkein D (June 2002). "Proteasome inhibitors in the treatment of B-cell malignancies". Clinical Lymphoma. 3 (1): 49-55. doi: ... "Cell. 137 (1): 133-45. doi:10.1016/j.cell.2009.01.041. PMC 2668214. PMID 19345192.. ...
In particularly large tumors and cancers with high white cell counts, such as lymphomas, teratomas, and some leukemias, some ... Two girls with acute lymphoblastic leukemia receiving chemotherapy. The girl at left has a central venous catheter inserted in ... DNA precursors/. antimetabolites. (S phase). Folic acid. *Dihydrofolate reductase inhibitor (Aminopterin. *Methotrexate# ... The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hodgkin's lymphoma. Follicular dendritic cell sarcoma. Extranodal NK/T-cell lymphoma, nasal type. MCPyV Merkel-cell carcinoma. ... A primary central nervous system lymphoma (PCNSL), also known as microglioma and primary brain lymphoma,[1] is a primary ... of all cases of lymphomas in HIV infections (other types are Burkitt's lymphomas and immunoblastic lymphomas). Primary CNS ...
Lymphoma and leukemia: These two classes arise from hematopoietic (blood-forming) cells that leave the marrow and tend to ... acute lymphoblastic leukemia and brain tumors are most common, except in Africa where non-Hodgkin lymphoma occurs more often.[ ... while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma and a cancer arising from fat cells ... and human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk of cancer, as seen in ...
Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... Its natural precursor, β-carotene, is considered safe, whereas the consumption of animal liver can lead to malformation, as the ... Male germ cells mutate at a much faster rate than female germ cells, and as the father ages, the DNA of the germ cells mutates ... This is because, as humans age, male germ cells acquire mutations at a much faster rate than female germ cells.[59][32][29] ...
Histopathology of the Thymus of Patients With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Complete Clinical ... The role of CCL21 in recruitment of T-precursor cells to fetal thymi. Lühikokkuvõte, Blood. 1. jaanuar 2005 ;105(1):31-9. 2005 ... Autoreactive thymic B cells are efficient antigen-presenting cells of cognate self-antigens for T cell negative selection., 110 ... Cell-Autonomous Defects in Thymic Epithelial Cells Disrupt Endothelial-Perivascular Cell Interactions in the Mouse Thymus, 4. ...
Nodal marginal zone B cell lymphoma. *Non-Hodgkin lymphoma. *Precursor B lymphoblastic leukemia ... Lymphoma and leukemia: These two classes of cancer arise from cells that make blood. Leukemia is the most common type of cancer ... while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma, and a cancer arising from fat cells ... such as giant cell carcinoma, spindle cell carcinoma, and small-cell carcinoma.[citation needed] ...
"The Lymphomas" (PDF). The Leukemia & Lymphoma Society. May 2006. p. 2. Retrieved 2008-04-07.. ... These immune cells originate as precursor cells, derived from bone marrow,[1] and develop into several distinct types of T ... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... Cytotoxic T cells (TC cells, CTLs, T-killer cells, killer T cells) destroy virus-infected cells and tumor cells, and are also ...
... pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia" ... Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... is a specific genetic abnormality in chromosome 22 of leukemia cancer cells (particularly chronic myeloid leukemia (CML) cells ... Nowell was a pathologist at the University of Pennsylvania, studying leukemia cells under the microscope when he noticed cells ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Subtypes include precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt's leukemia, and ... Four major kinds of leukemia Cell type. Acute. Chronic Lymphocytic leukemia. (or "lymphoblastic"). Acute lymphoblastic leukemia ... Hairy cell[edit]. Further information: Hairy cell leukemia § Treatment. Decision to treat. Patients with hairy cell leukemia ...
... acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma). ... The increased numbers of blood cells may not cause any symptoms, but a number of medical problems or symptoms may occur. The ... All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, ... Chronic myeloid leukemiaEdit. Chronic myeloid leukemia (CML) with the defining translocation t(9;22);Philadelphia chromosome ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hepatitis C virus: associated with splenic marginal zone lymphoma, lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma ... Hodgkin's lymphoma, follicular dendritic cell sarcoma, extranodal NK-T-cell lymphoma[9] ... Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except Hodgkin's lymphomas.[1] ...
Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... plasma cell leukemia.[23][41][42] Thus, a fundamental genetic instability in plasma cells or their precursors leads to the ... Stem cell transplant[edit]. Stem cell transplant can be used to treat multiple myeloma.[3] Stem cell transplants come with a ... The normal cell line most closely associated with MM cells is generally taken to be either an activated memory B cell or the ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hodgkin's lymphoma. Follicular dendritic cell sarcoma. Extranodal NK/T-cell lymphoma, nasal type. MCPyV Merkel-cell carcinoma. ... Since Burkitt lymphoma and other B-cell lymphomas are a clonal proliferative process, all tumor cells from one patient are ... The tumor cells have a similar appearance to the cancer cells of classical endemic Burkitt lymphoma. Sporadic lymphomas are ...
... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... The Lymphomas (PDF). The Leukemia & Lymphoma Society: 2. May 2006 [2008-04-07]. (原始内容存档 (PDF)于2008-07-06).. ,url-status=. 和. , ... Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells. The Journal of Biological Chemistry ... 辅助性CD4+/TFH(英语:Follicular B helper T cells)/Th3(英语:T helper 3 cell)/Th17(英语:T helper 17 cell)/调节
"The Lymphomas" (PDF). The Leukemia & Lymphoma Society. May 2006. p. 2. Retrieved 2008-04-07.. ... Common lymphoid precursor cells that migrate to the thymus become known as T-cell precursors (or thymocytes) and do not express ... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... Cytotoxic T cells (TC cells, CTLs, T-killer cells, killer T cells) destroy virus-infected cells and tumor cells, and are also ...
Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. ... acute myeloid leukemia lub acute myelogenous leukemia, AML lub acute non-lymphoblastic leukemia, ANLL) - grupa chorób ... Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. „Leuk Lymphoma". 49 (5), s. 852-63, May 2008. DOI ... Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hodgkin's lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white blood cells called ... The cell histology in Hodgkin's lymphoma is not as important as it is in non-Hodgkin's lymphoma: the treatment and prognosis in ... Micrograph showing a "popcorn cell", the Reed-Sternberg cell variant seen in nodular lymphocyte predominant Hodgkin lymphoma. H ...
... is a leukemia of megakaryoblasts, the precursors cells to megakaryocytes which form blood platelets.[46] Acute lymphoblastic ... Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... Leukemia is 10 to 15 times more common in children with Down syndrome.[20] In particular, acute lymphoblastic leukemia is 20 ... including acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia (AMKL) is increased while the risk of other ...
... each of which develops from cells originating in mesenchymal cells outside the bone marrow. Lymphoma and leukemia: These two ... In children, acute lymphoblastic leukemia and brain tumors are most common, except in Africa, where non-Hodgkin lymphoma occurs ... while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma and a cancer arising from fat cells ... and human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk of cancer, as seen in ...
Lymphoma. Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Lymphoid. Neoplasms by Histologic Type. Neoplasms ... Must have relapsed or refractory precursor B-cell acute lymphoblastic leukemia or acute lymphoblastic lymphoma. ... Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma. The safety and ... A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma. ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma , Houston (62 studies) * methodist hospital , Precursor Cell Lymphoblastic ... methodist hospital , Recruiting, Not yet recruiting, Available Studies , Precursor Cell Lymphoblastic Leukemia-Lymphoma (12 ... methodist hospital , Recruiting, Not yet recruiting, Available Studies , Precursor Cell Lymphoblastic Leukemia-Lymphoma , ... methodist hospital , Recruiting, Not yet recruiting, Available Studies , Precursor Cell Lymphoblastic Leukemia-Lymphoma , ...
Precursor lymphoid neoplasms are categorized as B lymphoblastic leukemia/lymphoma and T lymphoblastic leukemia/lymphoma. The B ... Precursor B-Cell Acute Lymphoblastic Leukemia/Lymphoma with L3 Morphology, Philadelphia Chromosome, MYC Gene Translocation, and ... or T-cell lineage. The immature cells in B-acute lymphoblastic leukemia/lymphoma can be small or medium sized with scant or ... Burkitt leukemia/lymphoma is now considered a mature B-cell neoplasm. It was formerly classified as precursor B ALL with L3 ...
... kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T-LBL/T- ... A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.. Lin ... A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma ... A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma ...
Lymphoid Leukemia, Acute; Lymphomas, Lymphoblastic; Precursor Cell Lymphoblastic Leukemia Lymphoma; Leukemia, Lymphoblastic; ... Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) Show All ,, Key Therapies for Precursor Cell ... Diseases Related to Precursor Cell Lymphoblastic Leukemia-Lymphoma. * Acute Myeloid Leukemia (Acute Myelogenous Leukemia) ... Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) Summary Description: A neoplasm characterized by ...
Precursor cell lymphoblastic leukemia lymphoma Tier 1 H96. Precursor cell lymphoblastic leukemia lymphoma Tier 2 H96. Precursor ... Precursor cell lymphoblastic leukemia lymphoma Tier 1 M96. Precursor cell lymphoblastic leukemia lymphoma Tier 2 M96. Precursor ... Precursor cell lymphoblastic leukemia lymphoma Tier 1 H384. Precursor cell lymphoblastic leukemia lymphoma Tier 1-4 H384. ... Precursor cell lymphoblastic leukemia lymphoma Tier 1 M384. Precursor cell lymphoblastic leukemia lymphoma Tier 1-4 M384. ...
leukemia, myeloid, acute; precursor cell lymphoblastic leukemia-lymphoma Gene Set. Dataset. GAD Gene-Disease Associations ... 11 genes associated with the disease leukemia, myeloid, acute; precursor cell lymphoblastic leukemia-lymphoma in GWAS and other ...
Leukemia, Lymphoblastic; Leukemia, Lymphoid, Acute; Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Lymphocytic Leukemia, Acute ... Lymphoma, Lymphoblastic. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several ... Precursor cell lymphoblastic leukemia-lymphoma (Leukemia, Lymphoblastic; Leukemia, Lymphoid, Acute; Lymphoblastic Leukemia; ... "precursor cell lymphoblastic leukemia-lymphoma"Drugs, active principles and "precursor cell lymphoblastic leukemia-lymphoma" ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma*Precursor Cell Lymphoblastic Leukemia-Lymphoma. *Precursor Cell Lymphoblastic ... "Precursor Cell Lymphoblastic Leukemia-Lymphoma" by people in this website by year, and whether "Precursor Cell Lymphoblastic ... Precursor Cell Lymphoblastic Leukemia-Lymphoma. *Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. *Precursor T-Cell ... "Precursor Cell Lymphoblastic Leukemia-Lymphoma" is a descriptor in the National Library of Medicines controlled vocabulary ...
... for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098-1107. ... Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Nicola Gökbuget, Hervé ... Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 131(14), 1522- ... Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6( ...
Precursor cell lymphoblastic leukemia-lymphoma. Clinical trials for drug safety evaluation, please follow the links below to ...
Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Lymphoid. Neoplasms by Histologic Type. Neoplasms. ... Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia ... Acute Lymphoblastic Leukemia Biological: KTE-C19 Drug: Fludarabine Drug: Cyclophosphamide Phase 1 Phase 2 ... Diagnosis of Burkitts leukemia/lymphoma according to the World Health Organization (WHO) classification or chronic myelogenous ...
20Division of Leukemia and Lymphoma, Childrens Cancer Center, National Center for Child Health and Development, Setagaya-ku, ... A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia. Leukemia. 2015;29(12):2445-2448. ... B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous disease that can be subdivided according to primary ... ALL: acute lymphoblastic leukemia; BCP-ALL: B-cell precursor ALL; B-others: BCP-ALL without conventional genetic abnormalities ...
2001) Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-5594. ... Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Akinori Yoda, Yuka Yoda, Sabina ... Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Akinori Yoda, Yuka Yoda, Sabina ... 2007) Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood ...
Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Lymphoid. Neoplasms by Histologic Type. Neoplasms. ... Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia. The safety and scientific ... Acute Lymphoblastic Leukemia Other: Cytology Specimen Collection Procedure Other: Laboratory Biomarker Analysis ... I. To provide a risk classification scheme for all patients with newly diagnosed acute lymphoblastic leukemia (ALL), which will ...
Fusion genes involving ZNF384 have recently been identified in B-cell precursor acute lymphoblastic leukemia, and 7 fusion ... Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis * Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics* ... Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism* * Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality ... ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic ...
A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell. 1995; 83(2):289-299. PubMed ... Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia. 2016; 30( ... B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy in children and involves uncontrolled ... Imamura T, Yano M, Asai D. IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients ...
... study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T- ... Leukemia, Lymphoid. *Precursor Cell Lymphoblastic Leukemia-Lymphoma. *Lymphoma. *Precursor T-Cell Lymphoblastic Leukemia- ... Patients with an unequivocal histologic diagnosis of precursor T-lymphoblastic. leukemia/lymphoma (World Health Organization [ ... Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma ...
To clarify the effect of MTHFR C677T on the risk of childhood acute lymphoblastic leukemia … ... C677T and childhood acute lymphoblastic leukemia have provided either controversial or inconclusive results. ... Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics* * Predictive Value of Tests * Risk Factors ... MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis Leuk Res. 2010 Dec;34(12):1596-600. doi: ...
lymphoma. 3. ClinicalTrials. Precursor Cell Lymphoblastic Leukemia-Lymphoma. D054198. EFO:0000220. acute lymphoblastic leukemia ... B-cell acute lymphoblastic leukemia. 3. ClinicalTrials. ClinicalTrials. Leukemia, Plasma Cell. D007952. EFO:0006475. plasma ... T-cell acute lymphoblastic leukemia. 3. ClinicalTrials. ClinicalTrials. Lymphoma, Follicular. D008224. EFO:0000096. neoplasm of ... angioimmunoblastic T-cell lymphoma. 3. ClinicalTrials. Leukemia, Lymphocytic, Chronic, B-Cell. D015451. EFO:0000095. chronic ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma. D054198. EFO:0000220. acute lymphoblastic leukemia. 3. ClinicalTrials. ... Lymphoma, Large-Cell, Anaplastic. D017728. EFO:0003032. anaplastic large cell lymphoma. 1. ClinicalTrials. ... Leukemia. D007938. EFO:0000565. leukemia. 3. ClinicalTrials. ClinicalTrials. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. ... Lymphoma. D008223. EFO:0000574. lymphoma. 2. ClinicalTrials. Neurilemmoma. D009442. EFO:0000760. malignant peripheral nerve ...
B-precursor lymphoblastic lymphoma. *Morphologically unclassifiable lymphoma. *Absence of both B-cell and T-cell phenotype ... in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. * Print ... they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma ... chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. ...
T-Cell Lymphoma , Precursor T-Lymphoblastic Lymphoma/Leukemia Patient Info: Currently in active treatment (initial surgery, ... Patient: Precursor T-Lymphoblastic Lymphoma/Leukemia * Patient Info: Currently in active treatment (initial surgery, receiving ...
T-Cell Lymphoma , Precursor T-Lymphoblastic Lymphoma/Leukemia Patient Info: Newly diagnosed (has not begun treatment), ... Patient: Precursor T-Lymphoblastic Lymphoma/Leukemia * Patient Info: Newly diagnosed (has not begun treatment), Diagnosed: over ...
Blood Cell Count. Bone Marrow Examination. Child, Preschool. Immunophenotyping. Precursor Cell Lymphoblastic Leukemia-Lymphoma ... had acute lymphoblastic leukaemia, 51.8% had acute myeloblastic leukemia and 7.8% were unclassified. Diagnosis was made at less ... than 10 years in 31.6% of cases and 72% of these were the lymphoblastic type. Anaemia [Hb , 11 g/dL was found in 85% of cases, ...
Precursor T-lymphoblastic lymphoma/leukemia The WHO classification subtypes for peripheral B-cell neoplasms are as follows:. * ... Mantle Cell Lymphoma. Diagnosis. Mantle cell lymphoma (MCL) is diagnosed in accordance with the World Health Organization ... of MCLs but is negative in all other B-cell lymphoid neoplasms except Burkitt lymphomas and lymphoblastic lymphomas ... Diffuse Large B-Cell Lymphoma. Diagnosis. In addition to its general guidance on diagnosis of lymphoma, the National ...
A tiling path 33K BAC array was used to study 28 children with acute lymphoblastic leukaemia (ALL) who had normal or failed G- ... Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*. From MEDLINE®/PubMed®, a database of the U.S. National Library of ... 12901975 - The emergence of ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treat.... 1581405 - A randomized ... A tiling path 33K BAC array was used to study 28 children with acute lymphoblastic leukaemia (ALL) who had normal or failed G- ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics. Wilms Tumor. Grant Support. ID/Acronym/Agency: CA 34233/CA/NCI NIH ... 2915919 - Are most secondary acute lymphoblastic leukemias mixed acute leukemias?. 7050389 - Monoclonal immunoglobulin of cll ... Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the ... Whereas the development of acute nonlymphocytic leukemia (ANLL) as an SMN is a well-recognized phenomenon, acute lymphoblastic ...
Burkitts leukemia or Burkitts lymphoma or primary mediastinal large B-cell lymphoma. or B-precursor lymphoblastic lymphoma or ... Burkitts Lymphoma, Burkitts Leukemia, Mediastinal Neoplasms, Lymphoblastic Lymphoma, Large Cell Anaplastic Lymphoma ... large cell anaplastic lymphoma. - Age > 15 years. - Written informed consent. Exclusion Criteria:. - Serious secondary diseases ... Multicenter Study to Optimise Therapy of B-ALL, Burkitts NHL and High-Grade Non-Hodgkins Lymphoma in Adults (Amend 7). Trial ...
  • We demonstrate that SMI-4a, a novel benzylidene-thiazolidine-2, 4-dione small molecule inhibitor of the Pim kinases, kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T-LBL/T-ALL) being highly sensitive. (nih.gov)
  • All cell lines except for Nalm 6 pre-B-LBL were derived from a myeloid leukemia. (nih.gov)
  • Sharma K, Singh U, Rai M, Shukla J, Gupta V, Narayan G, Kumar S. Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study. (rush.edu)
  • TSLP is produced by epithelial cells at sites of inflammation, where it activates myeloid dendritic cells and Th2 immune responses ( 18 , 19 ). (pnas.org)
  • Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. (nih.gov)
  • The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (springer.com)
  • Gentuzumab ozogamicin targets CD33, a myeloid lineage antigen, and is approved for acute myeloid leukemia ( 8 ). (aacrjournals.org)
  • Aberrant tyrosine kinase activity plays a critical role in many hematologic disorders, including chronic myeloid leukemia characterized by the constitutive activity of BCR-ABL. (aacrjournals.org)
  • Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia (Ph) chromosome, which results from t(9;22)(q34;q11) balanced reciprocal translocation ( 1 ). (aacrjournals.org)
  • Such group demonstrates expression of stem cell and myeloid markers in conjunction with the T cell antigens. (springer.com)
  • Biphenotypic acute leukaemia (BAL) is an uncommon type of leukemia which arises in multipotent progenitor cells which have the ability to differentiate into both myeloid and lymphoid lineages. (wikipedia.org)
  • The cells could display both myeloid lineage and lymphoid or undifferentiated morphology. (wikipedia.org)
  • If the score of only one lineage is higher than 2, the acute leukemia could be acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). (wikipedia.org)
  • Precursor lymphoid neoplasms are categorized as B lymphoblastic leukemia/lymphoma and T lymphoblastic leukemia/lymphoma. (hindawi.com)
  • As the name suggests, the cells that proliferate are immature lymphoid cells known as lymphoblasts, which have become halted in their development. (hindawi.com)
  • Bone marrow biopsy and aspirate revealed a hypercellular marrow almost completely replaced by a diffuse infiltrate of large lymphoid cells (Figures 1(a) and 1(b) ) with basophilic cytoplasm, cytoplasmic vacuoles, and large prominent nucleoli (L3/Burkitt lymphoma-like morphology) (Figure 2 ). (hindawi.com)
  • A peripheral smear showed few circulating abnormal lymphoid cells (5%) with the same cytologic features as the cells found in the bone marrow (Figure 3 ). (hindawi.com)
  • A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. (lookfordiagnosis.com)
  • Transcription factor IKZF1 (IKAROS) acts as a critical regulator of lymphoid differentiation and is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia. (haematologica.org)
  • B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy in children and involves uncontrolled expansion of B-lymphoid progenitors in the bone marrow. (haematologica.org)
  • Lymphoid leukemias are a group of leukemias affecting circulating lymphocytes , a type of white blood cells . (wikipedia.org)
  • Most lymphoid leukemias involve a particular subtype of lymphocytes, the B cells . (wikipedia.org)
  • The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia . (wikipedia.org)
  • B-cell leukemia describes several different types of lymphoid leukemia which affect B cells . (wikipedia.org)
  • Aggressive NK-cell leukemia (ANKL) is a lymphoid leukemia that is a deficiency NK cells. (wikipedia.org)
  • Natural killer (NK) cell therapy is used in pediatrics for children with relapsed lymphoid leukemia. (wikipedia.org)
  • [9] One problem when using NK cells in order to fight off lymphoid leukemia is the fact that it is hard to amount enough of them to be effective. (wikipedia.org)
  • This gene encodes a member of the T cell factor/lymphoid enhancer factor family of transcription factors. (cancerindex.org)
  • Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white blood cells) are found in the blood and bone marrow. (wikipedia.org)
  • Marginal zone lymphoma (including mucosa-associated lymphoid tissue [MALT] lymphoma). (oncolink.org)
  • We now report the development of thymic T cell lymphoblastic lymphomas in transgenic mice in which Stat5a or Stat5b is overexpressed within the lymphoid compartment. (nih.gov)
  • More recently, TdT was detected in transient populations of peripheric cells in young rats and mice (12), The biological function of TdT remains unknown although its biochemical properties and its cellular distribution have suggested a possible role in the differentiation of lymphoid cells and in the generation of the diversity of immunoglobulins (4, 13). (springer.com)
  • A B-cell leukemia is any of several types of lymphoid leukemia which affect B cells . (wn.com)
  • Leukemia is preceded by a dramatic expansion of cells resembling hematopoietic stem cells and lymphoid-committed progenitors prior to disease onset, accompanied by a blockage in B-cell differentiation at the early pro-B stage. (biologists.org)
  • Describe the features of follicular center cell (FCC) lymphomas. (brainscape.com)
  • Pediatric-type follicular lymphoma. (oncolink.org)
  • Composite chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma are biclonal lymphomas: a report of two cases. (semanticscholar.org)
  • The FDA approved Yescarta to treat adults (18 and older) with follicular lymphoma that has resisted treatment, or came back, after two other therapies. (ohsu.edu)
  • These phrases were contained in old descriptors which now are subsumed under NON-HODGKINS LYMPHOMA or FOLLICULAR LYMPHOMA. (nih.gov)
  • Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. (lls.org)
  • Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker? (bioportfolio.com)
  • The incidence of diffuse large B-cell lymphoma increases with age in both males and females. (oncolink.org)
  • The 2 primary immunodeficiency patients presented a T-cell lymphoblastic lymphoma and a diffuse large B-cell lymphoma. (acronymfinder.com)
  • Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma. (harvard.edu)
  • Primary composite lymphoma of the larynx, composed of diffuse large B-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, presenting as left subglottic tracheal fistula, esophageal diverticulum, and neck abscess. (semanticscholar.org)
  • Yescarta, Kymriah and Breyanzi are approved for adults with large B-cell lymphoma that resisted two or more therapies or that relapsed. (ohsu.edu)
  • This includes morphological descriptions of cell types like "small cleaved-cell" or "large-cell" or "undifferentiated" and grading such as "high grade" or "diffuse. (nih.gov)
  • A bone marrow biopsy was also obtained ( image ), which showed a diffuse infiltration by tumor cells with a similar morphology as the renal biopsy. (pathologyoutlines.com)
  • The renal biopsy showed a diffuse infiltrate of monotonous blastoid cells obliterating the normal renal architecture. (pathologyoutlines.com)
  • Needle biopsy of a retroperitoneal mass revealed diffuse infiltration of lymphoblastic tumor cells. (unboundmedicine.com)
  • it is very common in BAL patients, most of patients die due to the A low level of red blood cells in the bloodstream: Because the decline of hematopoietic function, need blood transfusion therapy Persistent fever, infection prolonged healing: Diffuse hemorrhage: which is dangerous and might lead to death. (wikipedia.org)
  • Within the B-cell and T-cell categories, two subdivisions are recognized: precursor neoplasms, which correspond to the earliest stages of differentiation, and more mature differentiated neoplasms. (medscape.com)
  • Source: Gamma delta T-cell neoplasms: a clinicopathological study of 11 cases. (lymphomation.org)
  • This randomized phase I trial is studying the side effects and best dose of two different schedules of sorafenib in treating patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic myelogenous leukemia. (clinicaltrials.gov)
  • I. Determine the maximum tolerated dose of sorafenib when administered in two different schedules in patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic myelogenous leukemia. (clinicaltrials.gov)
  • Composite Hodgkin lymphoma and chronic lymphocytic leukemia: a rare case. (semanticscholar.org)
  • We report the first characterization at the immunological and molecular level of 12 cases of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) from Tunisia. (cnrs.fr)
  • Describe the features of B small lymphocytic lymphoma/B cell CLL. (brainscape.com)
  • Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. (semanticscholar.org)
  • We report on 2 composite lymphomas occurring in elderly patients, morphologically characterized by the combination of peripheral T-cell lymphoma (PTCL) unspecified and B-cell small lymphocytic lymphoma. (semanticscholar.org)
  • Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. (cancerindex.org)
  • Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma presenting mostly in children and young adults. (cancerindex.org)
  • Pastorello RG, D'Almeida Costa F, Osório CABT, Makdissi FBA, Bezerra SM, de Brot M, Campos AHJFM, Soares FA, Vassallo J. Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. (harvard.edu)
  • brentuximab-vedotin, an ADC targeting CD30, is approved for the treatment of tumors arising from these cell populations, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma ( 2, 5, 6 ). (aacrjournals.org)
  • However, its systemic inactivation in adult mice induces T-cell acute lymphoblastic lymphoma (T-ALL), a tumor type known to carry CIC mutations, albeit with low incidence. (sebbm.es)
  • To estimate the 3-year survival rate of participants with first relapse or primary refractory precursor B-cell ALL and lymphoblastic lymphoma treated with risk-directed therapy. (clinicaltrials.gov)
  • The primary objectives of this study are to evaluate the safety and efficacy of KTE-C19 in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). (clinicaltrials.gov)
  • To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. (knowcancer.com)
  • This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma. (mayo.edu)
  • PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have refractory or relapsed Hodgkin's lymphoma. (bioportfolio.com)
  • Determine the response rate (overall and within strata) in both minimally pretreated, low-risk and heavily pretreated, high-risk children with refractory or relapsed Hodgkin's lymphoma treated with ifosfamide and vinorelbine with filgrastim (G-CSF). (bioportfolio.com)
  • Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. (freepatentsonline.com)
  • Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. (lls.org)
  • This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). (fredhutch.org)
  • NK cells are known for their ability to eradicate tumor cells without any prior sensitization to them. (wikipedia.org)
  • researchers have been able to isolate pure tumor cells at all stages. (jci.org)
  • Cancer stem cells (CSCs) constitute a sub-population of tumor cells that possess stem cell properties, such as self-renewal and the ability of differentiation. (cancerindex.org)
  • RATIONALE: Treating lymphocytes in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body. (bioportfolio.com)
  • Also shown is the CD4/CD8 profile of subcutaneous cervical lesions in a RAG/γc double KO mouse 3 wk after subcutaneous injection of fresh tumor cells (panels d and h). (nih.gov)
  • tumor cells preferentially infiltrate the sinusoids of the splenic red pulp, liver, and bone marrow. (lymphomation.org)
  • The tumor cells have a nonactivated cytotoxic T-cell immunophenotype and frequently carry a recurrent cytogenetic abnormality, isochromosome 7q. (lymphomation.org)
  • Tumor cells have higher rates of glucose uptake and aerobic glycolysis to meet energy demands for proliferation and metastasis. (medsci.org)
  • Here, we demonstrate that Pim-2 is required for glycolysis and energy production in colorectal tumor cells. (medsci.org)
  • Our results show that Pim-2 is highly expressed in colorectal tumor cells, and may be induced by nutrient stimulation. (medsci.org)
  • While knockdown of Pim-2 decreased energy production in colorectal tumor cells and increased their susceptibility to apoptosis. (medsci.org)
  • Our findings suggest that Pim-2-mediated aerobic glycolysis is critical for monitoring Warburg effect in colorectal tumor cells, highlighting Pim-2 as a potential metabolic target for colorectal tumor therapy. (medsci.org)
  • First, genes involved in normal B-cell development (e.g. (pnas.org)
  • Fusion genes involving ZNF384 have recently been identified in B-cell precursor acute lymphoblastic leukemia, and 7 fusion partners have been reported. (nih.gov)
  • The characteristic immunophenotype of weak CD10 and aberrant CD13 and/or CD33 expression was revealed to be a common feature of the leukemic cells harboring ZNF384-related fusion genes. (nih.gov)
  • The encoded protein contains a high mobility group-box DNA binding domain and participates in the regulation of cell cycle genes and cellular senescence. (cancerindex.org)
  • CAR T-cell therapy is a gene therapy because genes in the patient's T cells are reprogrammed to make CARs. (ohsu.edu)
  • PRDM14 functions in embryonic stem cell (ESC) maintenance to promote the expression of pluripotency-associated genes while suppressing differentiation genes. (biologists.org)
  • The second study uses microdissection and single-cell sequencing to establish the importance of JAK-STAT pathway genes in cHL, an observation that is mirrored in the ctDNA study. (prnewswire.com)
  • We report the occurrence of T cell receptor (TCR) beta and/or gamma gene rearrangements in two precursor B-ALL patients who had normally rearranged Ig genes. (cnrs.fr)
  • Genome-wide gene expression analysis of leukemic samples from precursor B-cell ALL patients (n=18) identified a set of genes differentially expressed in blasts at diagnosis day 0 (d0) and persisting on day 8 (d8). (uni-regensburg.de)
  • This test detects characteristic changes (rearrangements) in specific genes in T-cells. (labtestsonline.org)
  • Patients could undergo allogeneic hematopoietic stem-cell transplantation any time after cycle 1. (bloodjournal.org)
  • Depending on the condition, hematology specialists may treat a patient with a blood transfusion, stem cell transplantation, bone marrow transplant, radiotherapy, anticoagulation therapy or medication. (vitals.com)
  • Determine whether this treatment regimen can mobilize sufficient hematopoietic stem cells (CD34) for subsequent stem cell transplantation in minimally pretreated, low-risk patients. (bioportfolio.com)
  • Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. (bioportfolio.com)
  • Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative, Allogeneic Peripheral-Blood Stem-Cell Transplantation," The New England Journal of Medicine, Sep. (freepatentsonline.com)
  • The authors report the results of the first-in-human clinical trial of a novel interleukin-15 (IL-15) fusion protein to promote graft-versus-leukemia without enhancing graft-versus-host disease in patients with hematologic malignancies who relapsed after allogeneic stem cell transplantation. (prnewswire.com)
  • A blood-forming stem-cell transplantation is highly recommended. (wikipedia.org)
  • Intractable epilepsy in patients treated for childhood acute lymphocytic leukemia. (rush.edu)
  • Meeker TC, Hardy D, Willman C, Hogan T, Abrams J. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. (springer.com)
  • Asparaginase is a prescription medicine approved for use with other chemotherapy drugs to treat a certain type of acute lymphocytic leukemia (ALL is a type of cancer of the white blood cells). (rxwiki.com)
  • The aim of this study was to evaluate the relationship between body composition, metabolic profile, adipokines, and carotid intima-media thickness (cIMT) in young survivors of childhood acute lymphocytic leukemia (ALL). (dovepress.com)
  • Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. (semanticscholar.org)
  • Elderly patients with adverse cytogenetic abnormalities and high white blood cell count have a very poor prognosis. (hindawi.com)
  • The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. (pnas.org)
  • Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of malignancies of different biology and prognosis. (medscape.com)
  • In May 2017, Tyler underwent a stem-cell transplant. (wn.com)
  • Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. (springer.com)
  • Here we present a model of peripheral ALCL pathogenesis where the malignancy is initiated in early thymocytes, before T-cell receptor (TCR) β-rearrangement, which is bypassed in CD4/NPM-ALK transgenic mice following Notch1 expression. (cancerindex.org)
  • However, we find that a TCR is required for thymic egress and development of peripheral murine tumours, yet this TCR must be downregulated for T-cell lymphomagenesis. (cancerindex.org)
  • Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. (bioportfolio.com)
  • HSTCL is a rare aggressive type of extranodal lymphoma characterized by hepatosplenomegaly, bone marrow involvement, and peripheral blood cytopenias. (lymphomation.org)
  • Although HSTCL is the prototype peripheral T-cell lymphoma expressing the γδ T-cell receptor, non-HSTCL proliferations of γδ T cells can involve other extranodal sites, mainly skin and mucosa. (lymphomation.org)
  • Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. (nih.gov)
  • Bio Rad ( The T Cell Marker, CD3 Antigen and Antibodies, 2016). (freepatentsonline.com)
  • The T cells are sent to a lab where they are genetically modified to make the chimeric antigen receptor, or CAR. (ohsu.edu)
  • Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas , Scarfò et al. (prnewswire.com)
  • These preclinical studies support the use of CD37 as a target antigen for novel chimeric antigen receptor T-cell reagents. (prnewswire.com)
  • They demonstrate activity against B- and T-cell lymphomas both by single-antigen targeting and by dual-specific therapy in combination with anti-CD19. (prnewswire.com)
  • Inotuzumab ozogamicin targets CD22, a B-cell lineage antigen, and is approved for B-cell precursor acute lymphoblastic leukemia ( 7 ). (aacrjournals.org)
  • Polatuzumab vedotin targets CD79b, an antigen expressed in B cells and B-cell lymphoma ( 9 ). (aacrjournals.org)
  • To estimate levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block 1 of remission induction therapy for relapsed precursor B-cell ALL. (clinicaltrials.gov)
  • Remission induction for all participants consists of three blocks of therapy, wherein the first block is a novel immunotherapy regimen that includes cytotoxic chemotherapy, rituximab and infusion of haploidentical natural killer (NK) cells. (clinicaltrials.gov)
  • Participants with lymphoma must be in complete remission at the end of Block III. (clinicaltrials.gov)
  • Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction or flow cytometry. (bloodjournal.org)
  • In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (≥10 −3 ) received blinatumomab 15 µg/m 2 per day by continuous IV infusion for up to 4 cycles. (bloodjournal.org)
  • B-cell precursor ALL who are in remission but still have minimal residual disease (MRD). (lls.org)
  • A stem cell transplant may be an option for some people with precursor lymphoblastic lymphoma who go into remission after chemotherapy. (cancer.ca)
  • The therapy has led to long-term remission for children and adults with some types of leukemia and lymphoma. (ohsu.edu)
  • The patient achieved complete remission by an induction therapy for acute lymphoblastic leukemia, underwent allogeneic bone marrow transplantation, and has remained in complete remission for more than 3 years. (unboundmedicine.com)
  • Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma , Spina et al. (prnewswire.com)
  • Legionella bozemanii pulmonary abscess in a pediatric allogeneic stem cell transplant recipient. (biomedsearch.com)
  • This case report describes a pediatric stem cell transplant recipient presenting with cavitary pulmonary disease secondary to Legionella bozemanii infection. (biomedsearch.com)
  • Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. (springer.com)
  • Lymphoblastic lymphoma seen more commonly in children and adolescents -- account for 1/2 of pediatric lymphomas. (wikibooks.org)
  • Precursor B-cell acute lymphoblastic leukemia/lymphoma (ALL) is a common pediatric hematologic malignancy. (pathologyoutlines.com)
  • Children affected by ALCL may thus harbour thymic lymphoma-initiating cells capable of seeding relapse after chemotherapy. (cancerindex.org)
  • Treatment will consist of chemotherapy for SR participants, and chemotherapy followed by hematopoietic stem cell transplant (HSCT) for HR in first relapse. (clinicaltrials.gov)
  • The first block is a novel immunotherapy regimen that includes chemotherapy, rituximab and infusion of haploidentical natural killer (NK) cells. (clinicaltrials.gov)
  • The general treatment plan will consist of chemotherapy for standard-risk participants and chemotherapy followed by HSCT for high risk participants in first relapse of B-precursor ALL or lymphoblastic lymphoma. (clinicaltrials.gov)
  • This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. (mayo.edu)
  • Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. (mayo.edu)
  • Giving more than one drug (combination chemotherapy) may kill more cancer cells. (mayo.edu)
  • It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. (mayo.edu)
  • Determine the response rate in patients with angioimmunoblastic T-cell lymphoma after chemotherapy comprising fludarabine and cyclophosphamide. (bioportfolio.com)
  • Chemotherapy is the main treatment for lymphoblastic lymphomas. (cancer.ca)
  • RATIONALE: Drugs used in chemotherapy, such as gemcitabine and vinorelbine, use different ways to stop cancer cells from dividing so they stop growing or die. (bioportfolio.com)
  • Doctors may give the patient a short course of chemotherapy before giving them the CAR T cells in an IV drip. (ohsu.edu)
  • PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells , Kahn et al. (prnewswire.com)
  • Targeted killing of cancer cells without toxicity to normal cells, is one of the most significant considerations in cancer chemotherapy. (medsci.org)
  • [9] One can receive donations of NK cells from parents or relatives through bone marrow transplants. (wikipedia.org)
  • B-LBL and T-LBL can be considered either a lymphoma or leukemia, depending on how many areas of bone marrow have lymphoblasts in them. (cancer.ca)
  • If less than 25% of cells in the bone marrow are lymphoblasts, it is considered a lymphoblastic lymphoma. (cancer.ca)
  • Lymphoma may also spread to the bone marrow and to other organs in the body. (hopkinsmedicine.org)
  • The number of blood cells in your bone marrow. (rxwiki.com)
  • And the best news of all is that I just got the results of the 3 month bone marrow and my cells are 100% my sisters, with no evidence of cancer! (lymphomation.org)
  • Kroft, Steven H. / Precursor B-cell lymphoblastic lymphoma : A study of nine cases lacking blood and bone marrow involvement and review of the literature . (elsevier.com)
  • Bone marrow neoplastic niche in leukemia. (semanticscholar.org)
  • This is a long shot but, my grandpa has a rare form of leukemia and is in need of a stem cell/bone marrow donor. (wn.com)
  • Our team's exceptional expertise, on our Bone Marrow and Stem Cell Transplant page. (ohsu.edu)
  • It's best handled at centers - such as the Knight Cancer Institute - with deep experience doing stem cell and bone marrow transplants. (ohsu.edu)
  • The bone marrow biopsy showed a similar population of cells replacing most of the marrow. (pathologyoutlines.com)
  • Lymphoblasts in bone marrow were positive for CD10 and CD19 but negative for CD20, surface immunoglobulin, and T-cell antigens. (unboundmedicine.com)
  • Because the cells were immunoreactive for CD79a, CD10, and terminal deoxynucleotidyl transferase, the patient was diagnosed as having precursor B-lymphoblastic lymphoma (which is rare in adults) with bone marrow involvement. (unboundmedicine.com)
  • The cells show L3 morphology (Burkitt-like lymphoma) with coexpression of TdT and surface light chains in addition to an MYC gene translocation and Philadelphia chromosome. (hindawi.com)
  • We present an unusual case of a precursor B-cell ALL, in an 82-year-old woman, with L3 morphology (Burkitt-like lymphoma) that demonstrates coexpression of TdT and surface light chains. (hindawi.com)
  • In sub-Saharan Africa, the high incidence of Epstein-Barr virus (EBV)-induced Burkitt lymphoma/leukemia is tenfold to twentyfold higher, resulting in a much higher incidence of NHL. (oncolink.org)
  • The incidence of NHL is higher in whites than in African Americans, and Burkitt lymphoma/leukemia is more common in non-Hispanic whites (3.2 cases/million person-years) than in Hispanic whites (2.0 cases/million person-years). (oncolink.org)
  • A review of Surveillance, Epidemiology, and End Results (SEER) data revealed that 2.5 cases per 1 million person-years of Burkitt lymphoma/leukemia were diagnosed in the United States between 1992 and 2008, with more cases in males than in females (3.9:1.1). (oncolink.org)
  • Lymphoblastic lymphomas are an uncommon, but fast-growing (aggressive), type of non-Hodgkin lymphoma (NHL). (cancer.ca)
  • With non-Hodgkin lymphoma, cells in the lymphatic system grow out of control. (hopkinsmedicine.org)
  • About 85% of people with non-Hodgkin lymphoma in the U.S. have B-cell. (hopkinsmedicine.org)
  • Non-Hodgkin lymphoma is different from Hodgkin lymphoma. (hopkinsmedicine.org)
  • With Hodgkin lymphoma, cancer cells only make up a small part of the cells in a cancerous lymph node. (hopkinsmedicine.org)
  • In non-Hodgkin lymphoma, cancer cells make up most of a tumor. (hopkinsmedicine.org)
  • Hodgkin and non-Hodgkin lymphoma also differ in the way they spread and in how they are treated. (hopkinsmedicine.org)
  • Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma. (oncolink.org)
  • This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood non-Hodgkin lymphoma. (oncolink.org)
  • Lymphoma (Hodgkin lymphoma and NHL) is the third most common childhood malignancy, and NHL accounts for approximately 7% of cancers in children younger than 20 years in high-income countries. (oncolink.org)
  • This aggressive blood cancer is the most common type of non-Hodgkin lymphoma. (ohsu.edu)
  • These two papers elucidate the molecular landscape of classical Hodgkin lymphoma (cHL). (prnewswire.com)
  • 3. Mehta A, Gulati K, Jain M, Gulati S. Non-Hodgkin lymphoma in a child presenting as nephromegaly and acute renal failure. (pathologyoutlines.com)
  • Cutaneous lymphomas comprise a heterogeneous group of lymphoproliferative disorders with skin involvement and are classified as a subgroup of non-Hodgkin lymphomas. (scielo.br)
  • From 1981 to 2007, 100 children with non-Hodgkin lymphomas were admitted to the Hematology Unit of the Federal University of Minas Gerais Teaching Hospital. (scielo.br)
  • Lymphomas involve the skin either primarily or secondarily and are classified as a subgroup of non- Hodgkin lymphomas (NHL). (scielo.br)
  • Most non-Hodgkin lymphomas in the U.S. are B-cell lymphomas (about 85%), according to the American Cancer Society. (labtestsonline.org)
  • Chest radiographs may reveal signs of pneumonia and/or a prominent mediastinal mass in some cases of T-cell acute lymphoblastic leukemia (ALL). (medscape.com)
  • Childhood NHL is more common in males than in females, with the exception of primary mediastinal B-cell lymphoma, in which the incidence is almost the same in males and females. (oncolink.org)
  • have coined a 'thoracic sandwich sign' in reference to anterior-mediastinal lymphadenopathy encompassing the brachiocephalic vein on chest CT in a patient with T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. (lookfordiagnosis.com)
  • Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. (clinicaltrials.gov)
  • The involvement of childhood cancer is relatively rare, with relevant incidence rates of some cancers such as Acute Lymphoblastic Leukemia (ALL) and Wilms Tumor (WT). (usp.br)
  • Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (mayo.edu)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. (lls.org)
  • Correlation of HIWI and HILI Expression with Cancer Stem Cell Markers in Colorectal Cancer. (cancerindex.org)
  • The aim of the study was to evaluate the clinical significance of the HIWI and HILI expression and its relationship with cancer stem cells markers in 72 patients with colorectal carcinoma (CRC). (cancerindex.org)
  • The expression level of HIWI and HILI and cancer stem cells markers in paired cancerous and non-cancerous tissues was measured by real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. (cancerindex.org)
  • cancer cells, either by killing the cells or by stopping them from dividing. (bioportfolio.com)
  • Giving fludarabine and cyclophosphamide together with thalidomide may kill more cancer cells. (bioportfolio.com)
  • Cancer is when cells in the body change and grow out of control. (hopkinsmedicine.org)
  • Cancer is made up of abnormal cells that grow even though your body doesn't need them. (hopkinsmedicine.org)
  • If cancer cells are in your body long enough, they can grow into, or invade, nearby areas. (hopkinsmedicine.org)
  • Lymphoma is a kind of cancer that starts in the lymphatic system. (hopkinsmedicine.org)
  • T-cells can also kill some cancer cells. (hopkinsmedicine.org)
  • The cancer cells are usually special cells called Reed-Sternberg cells. (hopkinsmedicine.org)
  • cancer cells from dividing so they stop growing or die. (bioportfolio.com)
  • cancer cells. (bioportfolio.com)
  • High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition. (nih.gov)
  • High dose vitamin C inhibits proliferation of breast cancer cells through reducing glycolysis and protein synthesis]. (nih.gov)
  • Cancer Cell. (springer.com)
  • Cyclophosphamide is a prescription medicine used alone, or in combination with other medications to treat several types of cancer including lymphoma, leukemia, ovarian, and breast cancer. (rxwiki.com)
  • It works by interfering with the growth of rapidly multiplying cancer cells, by a process known as cross-linking tumor cell DNA. (rxwiki.com)
  • This specific enzyme works by interfering with natural substances necessary for cancer cell growth. (rxwiki.com)
  • a type of cancer of the white blood cells). (rxwiki.com)
  • It works by slowing or stopping the growth of cancer cells in your body. (rxwiki.com)
  • T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer that arises from clonal expansion of transformed T-cell precursors. (semanticscholar.org)
  • Stem cell donor match found for breast cancer survivor who now has leukemia. (wn.com)
  • area that is heavily populated and just a few meters away from the Bulacao Community School with a population of about 4, 000 school children who are particularly vulnerable to cell tower radiation, namely the impairment of memory and learning, cancer, leukemia and the like. (wn.com)
  • In the analysis of a real-world microarray dataset, the two Global Tests gave markedly different results, compared to SAM-GS, in identifying pathways whose gene expressions are associated with p53 mutation in cancer cell lines. (nih.gov)
  • CAR T-cell therapy is an inventive treatment that takes T cells from the patient's body and modifies them to destroy cancer cells. (ohsu.edu)
  • Receptor" means it can bind to a cancer cell, like a key fitting in a lock. (ohsu.edu)
  • This protein binds to specific proteins on the surface of cancer cells. (ohsu.edu)
  • That equips the modified T cells to target and kill the cancer cells. (ohsu.edu)
  • Once in the patient's bloodstream, the CAR T cells multiply and may be able to destroy all the cancer cells. (ohsu.edu)
  • The reprogrammed cells may stay in the body to fight cancer for years. (ohsu.edu)
  • Donor cells may be more effective at fighting cancer. (ohsu.edu)
  • however, aberrant expression is associated with tumor initiation in a wide variety of human cancers, including breast cancer and leukemia. (biologists.org)
  • The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. (lls.org)
  • Cancer cell energy metabolism deviates significantly from that of normal tissues. (medsci.org)
  • However, cancer cells perform higher rates of aerobic glycolysis with products of pyruvate and lactate, known as Warburg effect [ 2 ]. (medsci.org)
  • It is thought that cancer cells take this metabolic transformation not only to meet energy demand but also to maintain the redox homeostasis [ 3 ]. (medsci.org)
  • Due to the preference of aerobic glycolysis, cancer cells can be selectively targeted by disruption of their glucose metabolism [ 5 - 7 ]. (medsci.org)
  • These glycolytic factors are consistently and significantly expressed in cancer cells. (medsci.org)
  • Thus, factors that involve mTORC1 signaling activation may have potential to modulate aerobic glycolysis in cancer cells. (medsci.org)
  • Symptoms caused by blood cancer cells infiltration into tissues: Swollen lymph nodes Joint pain Swelling of the gums Enlargement of the liver and spleen Headache and vomiting: blood cancer infiltration into the wear performance of the central nervous system. (wikipedia.org)
  • Precision Cancer Medicine Precision medicine enables cancer specialists to identify and target cancer cells. (osu.edu)
  • His work also explores the development of novel/improved strategies for radiosensitization of cancer cells in an effort to protect normal cells and achieve a better therapeutic ratio. (osu.edu)
  • Dr. Jacob has co-authored more than 25 articles appearing in well-known science journals such as Molecular Cell, Cancer Research, Radiation Research and Molecular Biology of the Cell. (osu.edu)
  • A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. (nih.gov)
  • Patients with an unequivocal histologic diagnosis of precursor T-lymphoblastic leukemia/lymphoma (World Health Organization [WHO] classification). (knowcancer.com)
  • This research trial studies a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia. (clinicaltrials.gov)
  • I. To provide a risk classification scheme for all patients with newly diagnosed acute lymphoblastic leukemia (ALL), which will be used to assign treatment on Children?s Oncology Group (COG) frontline ALL treatment studies. (clinicaltrials.gov)
  • This classification divides NHL into two groups: those of B-cell origin and those of T-cell/natural killer (NK)-cell origin. (medscape.com)
  • The WHO modification of the REAL classification of NHL is based on morphology and cell lineage. (medscape.com)
  • However, the influential WHO Classification (published in 2001) emphasized a greater emphasis on cell lineage. (wikipedia.org)
  • Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B, Fonatsch C, Schwarzinger I. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. (springer.com)
  • The old classification system for lymphomas, was discarded for a simpler model. (nih.gov)
  • This is the current update and revision on the WHO classification of acute lymphoblastic leukemias. (springer.com)
  • Before 2008, the diagnosis of BAL was based on a score system proposed by the European Group for the Immunological Classification of Leukemias (EGIL) which could differentiate from other kinds of acute leukemia. (wikipedia.org)
  • Immunophenotyping of selected hematologic disorders--focus on lymphoproliferative disorders with more than one malignant cell population. (semanticscholar.org)
  • Careful morphologic study and immunophenotyping by flow cytometry or immunohistochemistry is helpful to arrive at the correct diagnosis, and to avoid confusion with other small blue cell tumors which may involve the kidney, such as Wilm s tumor ( J Pediatr Hematol Oncol 2008;30:471 ) , small cell carcinoma or Ewing s sarcoma/primitive neuroectodermal tumor. (pathologyoutlines.com)
  • Acute lymphoblastic leukemia/lymphoma is rare in the adult population, and the lymphoblasts that are characteristic of the disease show a spectrum of differentiation and have varied cytogenetic alterations. (hindawi.com)
  • similar to small lymphocytic lymphomas but shows plasmacytoid differentiation. (brainscape.com)
  • When a large biopsy or resection specimen is available for review, the morphologic differentiation between thymoma and T-cell ALL/LBL, in general, is straightforward. (humpath.com)
  • Differentiation of thymoma from T-cell ALL/LBL based on histologic examination can be confounded further by a thymoma that has a predominance of lymphocytes . (humpath.com)
  • A direct comparison with normal B cells, which are largely therapy resistant, confirmed the differentiation shift at the mRNA (n=10) and protein (n=109) levels. (uni-regensburg.de)
  • As regards type of leukaemia, 40.4% had acute lymphoblastic leukaemia, 51.8% had acute myeloblastic leukemia and 7.8% were unclassified. (who.int)
  • Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding. (biomedsearch.com)
  • A tiling path 33K BAC array was used to study 28 children with acute lymphoblastic leukaemia (ALL) who had normal or failed G-banded karyotypes. (biomedsearch.com)
  • Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. (springer.com)
  • Sawinska M, Ladon D. Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia. (springer.com)
  • A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). (springer.com)
  • Acute lymphoblastic leukemia, with a PH positive and a Philadelphia chromosome , is what he was told that he had. (wn.com)
  • The molecular consequence of the Ph chromosome is the generation of the BCR-ABL oncogene that encodes for the chimeric BCR-ABL oncoprotein, with constitutive kinase activity that promotes the growth advantage of leukemic cells ( 2 ). (aacrjournals.org)
  • The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name (for example, adult T-cell leukemia/lymphoma ). (wikipedia.org)
  • Small resting lymphocytes mixed with variable number of large activated cells. (wikipedia.org)
  • Precursor lymphoblastic lymphomas start when immature lymphocytes (called lymphoblasts) become abnormal during the earliest stages of their development. (cancer.ca)
  • B cells and T cells are types of lymphocytes. (cancer.ca)
  • B-lymphocytes (B-cells). (hopkinsmedicine.org)
  • T-lymphocytes (T-cells). (hopkinsmedicine.org)
  • They can be grouped by the type of lymphocytes they start in: B-cells or T-cells. (hopkinsmedicine.org)
  • in these cases, the cells were characterized as precursors of T or B lymphocytes (7-11). (springer.com)
  • T cells are lymphocytes - a type of white blood cell that fights infection as part of the immune system. (ohsu.edu)
  • Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded by a premalignant tumor with which it shares genetic abnormalities, including universal dysregulation of the cyclin D/retinoblastoma (cyclin D/RB) pathway. (jci.org)
  • Multiple myeloma (MM) is an age-dependent monoclonal tumor of BM plasma cells (PCs). (jci.org)
  • However, clinical features of TCF3-ZNF384-positive patients are markedly different from those of EP300-ZNF384-positive patients, exhibiting higher cell counts and a younger age at presentation. (nih.gov)
  • Patients with clinical evidence of active central nervous system (CNS) leukemia. (knowcancer.com)
  • The Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J. (medscape.com)
  • Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the demographic, clinical and genetic levels. (haematologica.org)
  • These γδ T-cell lymphomas display marked heterogeneity in clinical and histologic features. (lymphomation.org)
  • Therefore, we investigated the clinical relevance of 13 recurrent genetic alterations in 204 children treated uniformly for relapsed B-cell precursor ALL according to the ALL-REZ BFM 2002 protocol. (uni-regensburg.de)
  • Our doctors helped lead the clinical trial showing that CAR T-cell therapy for lymphoma not only extends survival but may improve quality of life after treatment. (ohsu.edu)
  • The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. (springer.com)
  • The objective of this study was to describe the clinical course of children with skin manifestations of lymphoma being followed-up at the hematology department of the Teaching Hospital of the Federal University of Minas Gerais. (scielo.br)
  • This information, along with clinical signs and symptoms and results of other laboratory tests, can help clarify a person's diagnosis, or evaluate for persistent, residual, or recurrent lymphoma. (labtestsonline.org)
  • abstract = "We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. (elsevier.com)
  • Three patients were classified as having primary cutaneous lymphoma, while in six the disease was systemic with cutaneous involvement. (scielo.br)
  • No deaths occurred in any of the children with primary cutaneous lymphoma. (scielo.br)
  • They can only be considered primary cutaneous lymphomas (PCL) when the initial presentation is in the skin and there is no evidence of extracutaneous involvement at diagnosis, following complete staging. (scielo.br)
  • Symptomatic AVN have been reported in 1-17% of children with acute lymphoblastic leukemia (ALL) during treatment or thereafter although an incidence of up to 72% of asymptomatic AVN has been detected with systematic screening by magnetic resonance imaging (MRI). (minervamedica.it)
  • It is a neoplasm of precursor cells or lymphoblasts committed to either a B- or T-cell lineage. (hindawi.com)
  • Human and mouse leukemic cell lines were incubated with the indicated concentrations of SMI-4a for 24 hours in serum-free medium and then viable cells were quantitated by trypan blue exclusion. (nih.gov)
  • B) Human non-T leukemic cell lines. (nih.gov)
  • C) The murine leukemic cell lines tested were established from pre-T-LBL (12/1. (nih.gov)
  • Furthermore, we discuss different mechanisms by which IKZF1 alterations impose therapy resistance on leukemic cells, including enhanced cell adhesion and modulation of glucocorticoid response. (haematologica.org)
  • Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia. (semanticscholar.org)
  • PRDM14-induced leukemic cells contain high levels of activated NOTCH1 and downstream NOTCH1 targets, including MYC and HES1, and are sensitive to pharmacological inhibition of NOTCH1 with the γ-secretase inhibitor DAPT. (biologists.org)
  • Finally, the abnormal pathways that sustain the self-renewal of leukemic stem cells are described as possible targets to completely eradicate leukemic clones. (aacrjournals.org)
  • In childhood acute lymphoblastic leukemia (ALL), persistence of leukemic blasts during therapy is of crucial prognostic significance. (uni-regensburg.de)
  • After treatment with blinatumomab in a population of patients with MRD-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders. (bloodjournal.org)
  • This study reports high rates of response (78%) and prolonged survival with blinatumomab immunotherapy for adults with minimal residual disease-positive precursor B-cell acute lymphoblastic leukemia. (prnewswire.com)
  • Most of biphenotypic leukemia in children is due to the rearrangement of MLL Besides them, other gene abnormalities has been reported. (wikipedia.org)
  • Unlike systemic NHL in which the most com-mon cell lineage is B, cases of PCL are generally T-cell related. (scielo.br)
  • T-cells are able to find viral proteins in a virus-infected cell and then destroy the infected cell. (hopkinsmedicine.org)
  • T-cells also send out proteins called cytokines. (hopkinsmedicine.org)
  • These proteins signal other types of white blood cells to the infected area. (hopkinsmedicine.org)
  • Signal transducer and activator of transcription (STAT) proteins are latent transcription factors that mediate a wide range of actions induced by cytokines, interferons, and growth factors.The rate of lymphoma induction was markedly enhanced by immunization or by the introduction of TCR transgenes.These data demonstrate the oncogenic potential of dysregulated expression of a STAT protein that is not constitutively activated, and that TCR stimulation can contribute to this process. (nih.gov)
  • As a consequence, the GRB2/GAB2/SOS complex causes constitutive activation of the RAS downstream pathway, thereby activating mitogen-activated protein (MAP) extracellular signal-regulated kinase (ERK)1/2 (MEK) and MAP kinase proteins and resulting in abnormal cell proliferation. (aacrjournals.org)
  • Aggressive or high-grade lymphoma. (hopkinsmedicine.org)
  • The rearrangement of MLL are related with different kinds of aggressive acute leukemias. (wikipedia.org)
  • This type of lymphoma tends to spread first to the lymph nodes near that organ or to sites other than the lymph nodes. (hopkinsmedicine.org)
  • The signature gene expression profile in TCF3-ZNF384-positive patients was enriched in hematopoietic stem cell features and related to that of EP300-ZNF384-positive patients, but was significantly distinct from that of TCF3-PBX1-positive and ZNF384-fusion-negative patients. (nih.gov)
  • IKZF1 gene defects are associated with inferior treatment outcome in both childhood and adult B-cell precursor acute lymphoblastic leukemia and occur in more than 70% of BCR-ABL1 -positive and BCR-ABL1 -like cases of acute lymphoblastic leukemia. (haematologica.org)
  • So far, the researchers have concluded that lineage of the T-cell receptor gene does not predict the behavior of the disease. (wikipedia.org)
  • It consists of the following subtypes: t(9;22)-BCR/ ABL t(v;11q23)-MLL rearrangement t(1;19)-E2A/PBX1 t(12;21)-ETV/ CBFα t(17;19)-E2A-HLF One interesting model of precursor B ALL shows aberrant function of a single gene, namely Pax5, as capable to change phenotype of B cells toward precursor cells. (wikipedia.org)
  • P. Early, H. Huang, M. Davis, K. Calame and L. Hood, An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: V H ,D and J H , Cell , 19:981 (1980). (springer.com)
  • Gene rearrangements in T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • Immunohistochemistry provided objective confirmation of the coexistence of the 2 malignancies, as did molecular biology by revealing clonal T-cell receptor gamma and immunoglobulin heavy chain gene rearrangements. (semanticscholar.org)
  • Activation of the ABL tyrosine kinase is a primary event in the genesis of CML, as shown by the retrovirally mediated insertion of a human BCR-ABL gene into murine hematopoietic stem cells and the creation of BCR-ABL transgenic mice ( 3 ). (aacrjournals.org)
  • The hybrid gene product ABL/BCR is an oncogene which could lead several types of leukemia including BAL. (wikipedia.org)
  • BCR/ABL induce cell adhesive and migratory abnormalities because the mutation will lead an abnormal response to chemokine SDF-1 MLL gene encode Histone-lysine N-methyltransferase (HRX), which is a histone methyltransferase. (wikipedia.org)
  • Within any normal population (sample) of T-cells, the cells and their gene rearrangement profiles are very diverse. (labtestsonline.org)
  • In lymphoma, the T-cells in affected tissue (such as blood, lymph node, or skin) are identical and their gene rearrangement profiles are likewise identical. (labtestsonline.org)
  • A T-cell receptor gene rearrangement test evaluates the T-cells in a person's sample to determine whether the majority of T-cell rearrangement profiles are diverse or identical. (labtestsonline.org)
  • The B acute lymphoblastic leukemia/lymphoma (ALL) is further classified into B-ALL not otherwise specified or those with recurrent genetic abnormalities. (hindawi.com)
  • T-Cell Lymphoblastic Lymphoma With Coexisting Langerhans Cell Histiocytosis--Li & Borowitz) Answers to these questions will appear in the September 2001 issue. (acronymfinder.com)
  • Of the seven FDA-approved ADCs, four target lineage-specific hematologic antigens that are not markedly differentially expressed in neoplastic versus nonneoplastic cells. (aacrjournals.org)
  • The incidence of allogeneic stem cell transplant will be analyzed. (clinicaltrials.gov)
  • 2. The method of claim 1, wherein said allogeneic anti-tumor T cell immune response further comprises at least about 5% circulating allogeneic type CD3 + T cells. (freepatentsonline.com)
  • A wide ratio of TA to hTERT expression between leukemia subtypes suggests phenotype-specific hTERT post-transcriptional deregulations. (ac.be)
  • Cutaneous T-cell lymphomas constitute a heterogenous group of lymphoproliferative diseases characterized by a clonal expansion of mature postthymic T-cells that infiltrate the skin. (scielo.br)
  • whereas no expression was found in 11 patients with adult T-cell leukemia-lymphoma. (lymphomation.org)
  • In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells. (nih.gov)
  • Over the past few years, much has been learned about the tumor suppressive function of IKZF1 during leukemia development and the molecular pathways that relate to its impact on treatment outcome. (haematologica.org)
  • Gathering health information about patients with acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best treatment. (clinicaltrials.gov)
  • Assess the number of circulating clonal T cells at presentation and during thalidomide treatment. (bioportfolio.com)
  • Multiple-gated acquisition (MUGA) scans or echocardiograms are needed when the diagnosis of acute lymphoblastic leukemia (ALL) is confirmed, because many chemotherapeutic agents used in the treatment of acute leukemia are cardiotoxic. (medscape.com)
  • It may also be offered when precursor lymphoblastic lymphoma comes back after treatment (recurs) or when it takes a long time to respond to treatment. (cancer.ca)
  • To describe health-related quality of life (HRQOL) reported by children and adolescents in responses to two interview questions during treatment for acute lymphoblastic leukemia (ALL) and compare their responses by age, gender, risk group, and time in treatment through a quantitative content analysis approach. (gwu.edu)
  • Despite risk-adapted treatment, survival of children with relapse of acute lymphoblastic leukemia (ALL) remains poor compared with that of patients with initial diagnosis of ALL. (uni-regensburg.de)
  • Leukemia-associated genetic alterations may provide novel prognostic factors to refine present relapse treatment strategies. (uni-regensburg.de)
  • CONCLUSIONS: Each leukemia subtype possesses specific telomere dysregulations that rely on phenotype, karyotype, response to treatment, and survival. (ac.be)
  • CAR T-cell therapy is a complex, multistep treatment. (ohsu.edu)
  • Treatment starts with collecting T cells from the patient's blood. (ohsu.edu)
  • Kymriah is approved for patients up to age 25 with B-cell precursor acute lymphoblastic leukemia that resisted treatment or came back after treatment (relapsed). (ohsu.edu)
  • A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25% marrow involvement. (elsevier.com)